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Abstract 
The purpose of this study was to determine if a correlation exists between suicide 
and CAG repeat length in Huntington’s disease. 
Methodology: 
A case-control study using the COHORT Study de-identified database was conducted.  
Responses were collected from 163 participants. Depression, substance abuse history and 
use of benzodiazepines were covariates.  Responses to the UHDRS behavioral section 
pertaining to the frequency and severity of suicidal ideation (“feels life is not worth 
living”, “has suicidal thoughts”) were analyzed.  
Results: 
Despite taking depression, benzodiazepine use, and history of substance abuse into 
account, there was a predictive relationship between CAG repeat length and frequency of 
suicidal ideation (p = .010). When the effect of depression was taken into account, there 
was no significant relationship between CAG repeat length and the severity of suicidal 
ideation. 
Recommendations: 
The findings from this quantitative analysis supported using CAG length in a 
clinician’s risk factor assessment to determine the frequency of suicidality.   
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CAG Repeat Length and Suicidality in Huntington's disease 
Chapter 1 
Introduction 
Huntington’s disease (HD) is an autosomal dominant, progressive 
neurodegenerative disorder, causing atrophy of the basal ganglia, specifically the caudate 
nucleus, putamen, and globus nucleus (Novak & Tabrizi, 2010; Roos, 2010; Ross & 
Tabrizi, 2011).  The disease is characterized by choreiform movements, dystonia, mood 
and personality disorders, and cognitive impairment (Novak & Tabrizi, 2010; Ross & 
Tabrizi, 2011).  The average age of HD symptom onset is approximately 39 years 
although pediatric cases have been reported (Huntington Study Group [HSG], 2011).  
Approximately 30,000 people in the United States (US) have clinical manifestations of 
HD, and an additional 150,000 healthy people are thought to be immediately at risk of 
developing HD (HSG, 2011).  There is no gender or definite racial predispositions and 
the disease is found throughout the world (HSG, 2011).  Prevalence rates are particularly 
high in selected genetically segregated areas, such as the Lake Maracaibo region of 
Venezuela (HSG, 2011).  Huntington’s disease is notably rare in Finland and Japan 
(HSG, 2011). 
Overview 
Huntington’s disease has been traditionally diagnosed in individuals having 36 or 
more cytosine, adenine, and guanine (CAG) repeats on the short arm of chromosome 4 
(Rosenblatt et al., 1996).  As a result of this abnormality, a mutated huntingtin protein is 
produced.  The number of CAG repeats on the huntingtin gene may cause variations in 
clinical presentation.  HD research, involving genetics, has revealed variations in disease 
  
 
presentation, severity of symptoms, and age of onset related to the number of CAG 
repeats on the huntingtin gene (Rosenblatt et al., 1996).  Larger numbers of CAG repeats 
are associated with younger onset age, and CAG trinucleotide expansions in juvenile HD 
are usually in the range of 80 to 100 repeats (Brinkman, Mexei, Theilmann, Almquist, & 
Hayden, 2007).  In addition, there may be differences in clinical presentation, including 
severity of movement disorder, psychiatric disease, cognitive dysfunction, and 
metabolism (Rosenblatt et al., 1996). 
Huntington’s disease patients progress to develop a combination of choreiform 
movements, dystonia, and parkinsonian features, including rigidity, postural instability 
and bradykinesia (Ross & Tabrizi, 2011).  Abnormal eye movements can be one of the 
earliest motor signs of HD. Dysarthria, dysphagia, and hypermetabolism with subsequent 
weight loss are typical later manifestations of the illness (Aziz et al., 2008).  The illness 
typically progresses over a period of 15 to 20 years after onset of symptoms.  The initial 
decade of symptomatic HD is characterized by minimal functional disability and 
independence with activities of daily living (Roos, 2010).  The last 5 to 10 years of HD 
can lead to profound physical and psychiatric debility (Roos, 2010).  As a result, many 
affected individuals require 24-hour nursing care and/or extensive assistance with 
activities of daily living.  The average age at death is 54 to 55 years of age (Harper, 
2005). 
In addition, different cognitive domains may be impaired, including attention, 
executive function, and sequencing (Roos, 2010).  Cortical deficits, such as aphasia, 
agnosia, and apraxia, may also be present (Roos, 2010).  Insight and central language 
function generally remain unaffected even in advanced stages (Roos, 2010).  Psychiatric 
  
 
disease is also common, typically manifesting as psychosis, affective disorders, suicidal 
ideation, and apathy.  Individuals with HD develop significant personality changes, 
affective psychosis, or schizophrenic psychosis (Rosenblatt, 2007).  Prior to the onset of 
clinically manifest disease, they tend to score high on measures of depression, hostility, 
obsessive-compulsiveness, anxiety, interpersonal sensitivity, phobic anxiety, and 
psychoticism (Duff et al, 2007).  Behavioral disturbances, such as intermittent 
explosiveness, apathy, aggression, alcohol abuse, sexual dysfunction and deviations, and 
increased appetite, are common; delusion and paranoia are common, and hallucinations 
are less common (Anderson & Marder, 2001).  Unlike motor and cognitive dysfunction, 
psychiatric changes tend not to progress with disease severity (Anderson & Marder, 
2001).  
Suicide.  Individuals with Huntington’s disease are more likely than the general 
population to commit suicide (Fiedorowicz, Mills, Ruggle, Langbehn, & Paulsen, 2011; 
Novak & Tabrizi, 2010).  A survey of 4171 carriers of the Huntington’s gene with pre-
manifest and manifest disease found that 17.5% of suicidal thoughts occurred at or 
around the time of testing, and 10% of those had made at least one suicide attempt in the 
past (Novak & Tabrizi, 2010).  Suicidal ideation was highest in gene carriers who were 
beginning to become symptomatic and in those who were beginning to lose independence 
and functional ability (Novak & Tabrizi, 2010).  Risk factors for suicide are depression 
and impulsivity although some individuals with the disease have suicidal ideation in the 
absence of depression; for some, thoughts of suicide seem to be a rational response to 
their imminent loss of independence (Novak & Tabrizi, 2010).  Other risk factors for 
  
 
completed suicide in HD include male gender and lack of offspring; however, actual 
suicide attempts are greater in the female HD population (Fiedorowicz et al., 2011). 
Problem Statement and Goal 
The purpose of this quantitative analysis is to identify if there is a correlation 
between suicide and CAG repeat length in Huntington’s disease.  The goal of this 
research would be early identification, assessment, and treatment of suicidal behaviors to 
reduce the number of suicide attempts and completions in the HD patient population.  
The research questions of this proposed research include the following: 
1. What is the correlation between CAG repeat length and frequency of suicidal 
ideation? 
2. What is the correlation between CAG repeat length and severity of suicidal 
ideation? 
3. Does the Unified Huntington’s Disease Rating Scale (UHDRS) behavioral 
assessment accurately represent suicidal behavior of Huntington’s disease 
patients? 
Significance and Need for Study 
Death by suicide among individuals affected by HD is one of the serious 
consequences reported for this disease.  In 1872, a physician, George Huntington, 
referred to a characteristic of the disease that would later acquire his name as “a form of 
insanity which leads to suicide” (Rubin, 2003, p. 8).  The incidence of suicide and the 
conditions that predispose one to suicide is higher in HD than in the general population, 
including depression and isolation from the community, which occur commonly in HD 
(Rubin, 2003).  Completed suicide rates have been reported to be as high as 13% in 
  
 
Huntington’s disease, reflecting a seven-to-12-fold increase from the general population 
(Paulsen et al., 2005).  Comparison with other research suggested that suicide rates in HD 
remain higher than then those found in other medical conditions and neurodegenerative 
disorders (Paulsen et al., 2005). 
Much of research on suicide risk in Huntington’s disease has been centered on 
persons undergoing genetic testing.  Less focus has been placed on suicidal ideation over 
the different stages of pre-manifest and manifest HD (Paulsen et al., 2005).  The 
management of a suicidal HD patient potentially involves three components.  The first 
component is the identification and treatment of existing psychiatric disorders (Mann, 
2003).  The second component is the assessment of suicide risk and limitation of access 
to lethal methods of suicide (Mann, 2003).  The last component is the identification of the 
diathesis, which may in turn reduce the propensity to attempt suicide (Mann, 2003).  
There are currently no suicide prevention guidelines specific to Huntington’s disease.  If 
a predictive relationship is found to exist between CAG length and suicide, CAG repeat 
analysis may become a component when assessing suicide risk factors in a HD patient.  
Research Hypothesis 
 There is consistent evidence suggesting that genetic factors play a role in the 
predisposition to suicidal behavior in the general population (Ozalp, 2009).  Family, twin, 
and adoption studies have demonstrated that there is a genetic dimension to suicide 
(Ozalp, 2009).  Although there is some overlap between suicide and mood disorders even 
among psychiatric groups with the highest risk, some patients never attempt suicide, 
indicating the importance of a diathesis or genetic link to suicide that is independent of 
the underlying psychiatric disorder (Ozalp, 2009).  Among individuals with HD, suicide 
  
 
is more common than in the general population and accounts for 5 to 7% of deaths.  Over 
25% of individuals with HD attempt suicide at least once (Ozalp, 2009).  Some factors, 
which may contribute to suicide risk, have previously been identified, but no studies have 
investigated if there is a correlation between CAG length and suicide in Huntington’s 
disease, which leads to the following hypotheses.  
Hypothesis 1.  CAG repeat length significantly predicts the frequency of suicidal 
ideation, when controlling for depression, substance abuse history, and use of 
benzodiazepines 
Hypothesis 2.  CAG repeat length significantly predicts the severity of suicidal ideation, 
when controlling for depression, substance abuse history, and use of benzodiazepines. 
Hypothesis 3.  The UHDRS behavioral assessment accurately represents suicidal 
behavior of Huntington’s disease patients. 
 
 
 
 
 
 
 
 
 
 
 
  
 
Definition of Terms 
 Adenine.  Adenine (A) is one of four chemical bases in DNA with the other three 
being cytosine (C), guanine (G), and thymine (T).  Within the DNA molecule, adenine 
bases located on one strand form chemical bonds with thymine bases on the opposite 
strand.  The sequence of four DNA bases encodes the cell's genetic instructions.  A form 
of adenine called adenosine triphosphate (ATP) serves as an energy storage molecule and 
is used to power many chemical reactions within the cell (National Institute of 
Neurological Disease and Stroke, 2014). 
 Allele.  An allele is one of two or more versions of a gene.  An individual inherits 
two alleles for each gene: one from each parent.  If the two alleles are the same, the 
individual is homozygous for that gene.  If the alleles are different, the individual is 
heterozygous.  Although the term "allele" was originally used to describe variation 
among genes, it now also refers to variation among non-coding DNA sequences 
(National Institute of Neurological Disease and Stroke, 2014). 
 Agnosia.  Agnosia is characterized by an inability to recognize and identify 
objects or persons.  People with agnosia may have difficulty recognizing the geometric 
features of an object or face or may be able to perceive the geometric features, but not 
know what the object is used for or whether a face is familiar or not.  Agnosia can be 
limited to one sensory modality, such as vision or hearing.  For example, a person may 
have difficulty in recognizing an object as a cup or identifying a sound as a cough.  
Agnosia can result from strokes, dementia, developmental disorders, or other 
neurological conditions.  It typically results from damage to specific brain areas in the 
  
 
occipital or parietal lobes of the brain (National Institute of Neurological Disease and 
Stroke, 2014). 
 Aphasia.  Aphasia is difficulty in expressing oneself when speaking, trouble 
understanding speech, and difficulty with reading and writing.  Aphasia is not a disease, 
but a symptom of brain damage (National Institute of Neurological Disease and Stroke, 
2014). 
 Apraxia.  Apraxia is characterized by loss of the ability to execute or carry out 
skilled movements and gestures, despite having the desire and the physical ability to 
perform them.  Apraxia results from dysfunction of the cerebral hemispheres of the brain, 
especially the parietal lobe, and it can arise from many diseases or damage to the brain 
(National Institute of Neurological Disease and Stroke, 2014). 
 Autosomal dominance.  Autosomal dominance is a pattern of inheritance 
characteristic of some genetic diseases.  "Autosomal" means that the gene in question is 
located on one of the numbered, or non-sex, chromosomes.  "Dominant" means that a 
single copy of the disease-associated mutation is enough to cause the disease.  This is in 
contrast to a recessive disorder in which two copies of the mutation are needed to cause 
the disease (National Institute of Neurological Disease and Stroke, 2014). 
 Bradykinesia.  Bradykinesia is a decrease in spontaneity and movement.  It is 
one of the features of extrapyramidal disorders (National Institute of Neurological 
Disease and Stroke, 2014). 
 Chorea.  Chorea is comprised of involuntary, forcible, rapid, jerky movements 
that may be subtle or become confluent, markedly altering normal patterns of movement.  
Hypotonia and pendular reflexes are often associated.  Conditions, which feature 
  
 
recurrent or persistent episodes of chorea as a primary manifestation of disease, are 
referred to as choreatic disorders.  Chorea is also a frequent manifestation of basal 
ganglia diseases (National Institute of Neurological Disease and Stroke, 2014). 
 Chronic.  Chronic refers to a disease or condition that persists or progresses over 
a long period of time (National Institute of Neurological Disease and Stroke, 2014). 
 Cytosine.  Cytosine is one of four chemical bases in DNA, the other three being 
adenine, guanine, and thymine.  Within the DNA molecule, cytosine bases, located on 
one strand, form chemical bonds with guanine bases on the opposite strand.  The 
sequence of four DNA bases encodes the cell's genetic instructions (National Institute of 
Neurological Disease and Stroke, 2014). 
 Cytosine adenine guanine or CAG.  DNA repeats of cytosine, adenine, and 
guanine on the short arm of chromosome 4 are known as CAG  (National Institute of 
Neurological Disease and Stroke, 2014). 
Deoxyribonucleic acid.  Deoxyribonucleic acid is the chemical name for the 
molecule that carries genetic instructions in all living things.  The DNA molecule consists 
of two strands that wind around one another to form a shape known as a double helix.  
Each strand has a backbone made of alternating sugar (deoxyribose) and phosphate 
groups.  Attached to each sugar is one of four bases: adenine, cytosine, guanine, and 
thymine.  The two strands are held together by bonds between the bases: adenine bonds 
with thymine, and cytosine bonds with guanine.  The sequence of the bases along the 
backbones serves as instructions for assembling protein and RNA molecules (National 
Institute of Neurological Disease and Stroke, 2014). 
  
 
Dysarthria.  Dysarthria is a disturbance of speech due to emotional stress, due to 
brain injury, or to paralysis, incoordination, or spasticity of the muscles used for speaking 
(National Institute of Neurological Disease and Stroke, 2014). 
 Dysphagia.  Dysphagia is difficulty in swallowing (National Institute of 
Neurological Disease and Stroke, 2014). 
 Dystonia.  Dystonia is involuntary, sustained or spasmodic, patterned, and 
repetitive muscle contractions, frequently causing twisting, flexing or extending, and 
squeezing movements or abnormal postures (National Institute of Neurological Disease 
and Stroke, 2014). 
 Gene.  A gene is a functional and physical unit of heredity passed from parent to 
offspring. Genes are pieces of DNA, and most genes contain the information for making 
a specific protein (National Institute of Neurological Disease and Stroke, 2014). 
 Guanine.  Guanine is one of four chemical bases in DNA with the other three 
being adenine, cytosine, and thymine.  Within the DNA molecule, guanine bases, located 
on one strand, form chemical bonds with cytosine bases on the opposite strand.  The 
sequence of four DNA bases encodes the cell's genetic instructions (National Institute of 
Neurological Disease and Stroke, 2014). 
 Huntingtin gene.  The huntingtin gene (HTT) has one region that contains a 
particular DNA segment known as a CAG trinucleotide repeat.  This segment is made up 
of a series of three DNA building blocks (cytosine, adenine, and guanine) that appear 
multiple times in a row.  Normally, the CAG segment is repeated 10 to 35 times within 
the gene.  Although the exact function of this protein is unknown, it appears to play an 
important role in nerve cells (neurons) in the brain and is essential for normal 
  
 
development before birth.  Huntingtin is found in many of the body's tissues, with the 
highest levels of activity in the brain.  Within cells, this protein may be involved in 
chemical signaling, transporting materials, attaching (binding) to proteins and other 
structures, and protecting the cell from self-destruction (apoptosis) (National Institute of 
Neurological Disease and Stroke, 2014). 
 Huntington Study Group.  The Huntington Study Group is a non-profit group of 
clinical investigators from medical centers in the United States, Canada, Europe, 
Australia, New Zealand, and South America, who are experienced in the care of 
Huntington patients and dedicated to clinical research of Huntington disease.  The HSG 
was formed in 1993, prompted by the recognition that clinical research in HD required 
the participation of large numbers of research participants under the cooperative effort of 
skilled and experienced research physicians (Huntington Study Group, 2011). 
 Hypermetabolism.  Hypermetabolism refers to a state of increased metabolism 
where by the body's rate of energy production rises above normal (National Institute of 
Neurological Disease and Stroke, 2014). 
 Mutation.  A mutation is a change in a DNA sequence.  Mutations can result 
from DNA copying mistakes made during cell division, exposure to ionizing radiation, 
exposure to chemicals called mutagens, or infection by viruses.  Germ-line mutations 
occur in the eggs and sperm and can be passed on to offspring although somatic 
mutations occur in body cells and are not passed on (National Institute of Neurological 
Disease and Stroke, 2014). 
 Protein.  A protein is a large molecule composed of one or more chains of amino 
acids in a specific order; the order is determined by the base sequence of nucleotides in 
  
 
the gene that codes for the protein.  Proteins are required for the structure, function, and 
regulation of the body's cells, tissues, and organs, and each protein has unique functions.  
Examples of proteins include hormones, enzymes, and antibodies (National Institute of 
Neurological Disease and Stroke, 2014). 
 Suicide.  Suicide is a death caused by self-directed injurious behavior with any 
intent to die as a result of the behavior (National Institute of Neurological Disease and 
Stroke, 2014). 
 Suicide attempt.  A suicide attempt is a non-fatal, self-directed, potentially 
injurious behavior with any intent to die as a result of the behavior.  A suicide attempt 
may or may not result in injury (National Institute of Neurological Disease and Stroke, 
2014). 
 Suicidal ideation.  Suicidal ideation involves thinking about, considering, or 
planning for suicide (National Institute of Neurological Disease and Stroke, 2014). 
 Unified Huntington’s disease Rating Scale.  The UHDRS is a research tool 
developed by the Huntington Study Group to provide a uniform assessment of the clinical 
features and course of HD.  The UHDRS has undergone extensive reliability and validity 
testing and has been used as a major outcome measure by the HSG in controlled clinical 
trials.  The components of the UHDRS include the following: 
1. Motor Assessment  
2. Cognitive Assessment  
3. Behavioral Assessment  
4. Independence Scale  
5. Functional Assessment  
  
 
6. Total Functional Capacity (TFC) (HSG, 2011) 
 Unified Huntington’s Disease Rating Scale behavioral assessment.  Use the 
following keys to rate both severity and frequency: 
 Severity Frequency 
 0 = absent 
 1 = slight, questionable 
 2 = mild 
 3 = moderate 
 4 = severe 
 Sad mood.  A sad mood is feeling sad, sad voice expression, tearfulness, inability 
to enjoy anything. 
 Low self-esteem/guilt.  Low self-esteem/guilt includes self-blame, self-
deprecation, feelings of being a bad or unworthy person, and feelings of failure. 
 Anxiety.  Anxiety includes worries, anticipation of the worst, and fearful 
anticipation. 
 Suicidal thoughts.  When one has suicidal thoughts, he or she feels life not worth 
living, may active suicidal intent, and/or be preparing for the act. 
 Disruptive behavior.  Disruptive behavior includes being impatient, demanding, 
inflexible, physical violence, verbal outbursts, threatening, foul, or using abusive 
language. 
 Irritable behavior.  Irritable behavior includes being impatient, demanding, 
inflexible, driven and impulsive, and uncooperative. 
 Obsessions.  Obsessions are recurrent and persistent ideas, thoughts, or images. 
  
 
 Compulsions.  Compulsions are repetitive, purposeful, and intentional behaviors. 
 Delusions.  Delusions are fixed false beliefs, which are not culturally shared. 
 Hallucinations.  Hallucinations are a perception without physical stimulus and 
can include the following: auditory, visual, tactile, gustatory, and olfactory 
hallucinations.   
 Example Questions: 
1. Does the investigator believe the subject is confused? 
Yes or No 
2.  Does the investigator believe the subject is demented? 
Yes or No 
3.  Does the investigator believe the subject is depressed? 
Yes or No 
4.  Does the subject require pharmacotherapy for depression? 
Yes or No (HSG, 2011) 
Summary 
 Huntington disease is an autosomal-dominant neurodegenerative disease, 
characterized by cognitive disturbances, motor abnormalities, and psychiatric symptoms, 
caused by an expanded CAG repeat on the short arm of chromosome 4.  Suicidal 
ideation, suicide attempts, and completed suicides are frequent findings in individuals 
with Huntington’s disease.  The prevalence of suicide has been reported to be 20% in 
both pre-motor and motor-symptomatic mutation carriers (Hubers et al., 2012).  Much of 
the research to date on suicide has involved critical periods of time during the course of 
the disease and possible risk factors, such as depression, impulsivity, and substance 
  
 
abuse.  The relationship between CAG length and suicide has not been previously 
studied.  Suicide is one of the few potentially preventable causes of premature death in 
Huntington’s disease and an improved understanding of potential risk factors for suicide, 
including CAG length, is worthy of attention and exploration.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Chapter 2 
Review of Literature 
Huntington Disease and Suicide 
Suicidal behavior spans a spectrum that ranges from completed suicide, to suicide 
attempts, to suicidal ideation (Mann, 1998).  Suicide can be defined as suicidal ideation, 
suicide attempt, or completed suicide (Crosby, Ortega, & Melanson, 2011, p. 23).  To 
further clarify, suicide is a “death caused by self-directed injurious behavior with any 
intent to die as a result of the behavior” (Crosby et al., 2011, p. 23).  A suicide attempt is 
“a non-fatal, self-directed potentially injurious behavior with an intent to die as a result of 
the behavior.  The suicide attempt may or may not result in an injury” (Crosby et al., 
2011, p. 23).  Suicidal ideation is “thinking about, considering, or planning for suicide” 
(Crosby et al, 2011, p. 23).  
Individuals with HD develop significant psychological disease, personality 
changes, affective psychosis, or schizophrenic psychosis (Rosenblatt et al., 2007).  Prior 
to the onset of HD, they tend to have elevated scores on measures of depression, hostility, 
impulsivity, obsessive-compulsiveness, anxiety, interpersonal sensitivity, phobic anxiety, 
and psychoticism (Duff, Paulsen, Beglinger, Langbehn, & Stoudt, 2007).  Behavioral 
disturbances, such as intermittent explosiveness, apathy, aggression, alcohol abuse, 
sexual dysfunction and deviations, and increased appetite, are frequently associated with 
the disease (Pagon, Adam, & Bird, 2010).  In addition, paranoid delusions are common; 
whereas, visual and auditory hallucinations are not as likely (Pagon et al., 2010).  
 The incidence of depression and suicide in preclinical and symptomatic 
individuals is significantly more common in HD patients than the general population 
  
 
(Paulsen et al., 2005).  The etiology of depression in HD is unclear; it may be a 
pathologic, rather than a psychological, consequence of having the disease (Slaughter, 
Martens, & Slaughter, 2001).  Suicide and suicidal ideation are common in persons with 
HD, but the incidence rate changes with disease course and predictive testing results 
(Almqvist, Bloch, Brinkman, Craufurd, & Hayden, 1999).  Paulsen et al. (2005) 
suggested that suicide in patients with Huntington’s disease occurs at a broad rate 
between seven and 200 times more often than in the general population (p. 725).  
Previous studies evaluating suicidal risk and actual completion in Huntington’s disease 
vary greatly in methodology, making direct comparisons difficult (Paulsen et al., 2005).  
In one of the largest studies to date, Almqvist et al. (1999) evaluated the frequency of 
catastrophic events (CE), which include suicide, suicide attempts, and psychiatric 
hospitalizations, at predictive testing centers worldwide after collecting HD-predictive 
testing results through questionnaires (p. 1294).  A total of 44 persons in a cohort of 
4,527 (0.97%) test participants had a CE, which resulted in the following: five successful 
suicides, 21 suicide attempts, and 18 hospitalizations for psychiatric reasons (Almqvist et 
al. 1999, p. 1294).  All persons committing suicide had signs of HD, whereas 11 of 21 
(52.4%) persons attempting suicide and eight of 18 (44.4%) who had a psychiatric 
hospitalization were symptomatic.  A total of 11 of 13 (84.6%) asymptomatic persons 
who experienced a CE during the first year after HD-predictive testing received an 
increased-risk result (p. 1295).  Factors associated with an increased risk of a CE 
included a psychiatric history less than or equal to five years prior to testing and 
unemployed status (Almqvist et al., 1999, p. 1296). 
  
 
 Hubers et al. (2012) investigated the prevalence, clinical association, and 
predictors of suicide in Huntington’s disease.  Suicide was investigated in 152 HD 
mutation carriers and 56 non-carriers, and suicide was considered present if the score on 
the item “suicidal ideation” of the Problem Behaviours Assessment (PBA) was greater 
than one point.  After 2 years, 100 mutation carriers who were free of suicide at baseline 
were re-assessed.  Associations and predictors of suicide were analyzed using 
multivariate logistic regression analysis (Hubers et al., 2012).  Associations and 
predictors of suicide were analyzed using multivariate logistic regression analysis 
(Hubers et al., 2012).  The results indicated 11 (20%) pre-motor and 20 (20%) motor-
symptomatic mutation carriers were considered suicidal compared to none of the non-
carriers (Hubers et al., 2012).  Suicidal mutation carriers were (a) more likely to use 
antidepressants (odds ratio [OR] = 5.3); (b) were more often apathetic (OR = 2.8); (c) 
more often had a depressed mood, according to the PBA (OR = 5.9); and (d) were more 
often diagnosed with a DSM-IV depression diagnosis (OR = 4.7; Hubers et al., 2012).  
Independent associations were more frequent use of antidepressants (OR = 4.0) and 
presence of a depressed mood (OR = 4.2; Hubers et al., 2012).  Longitudinally, depressed 
mood (OR = 10.6) at baseline was the only independent predictor of suicide at follow-up 
(Hubers et al., 2012).  Hubers et al. (2012) concluded it is important for health care 
providers to screen both pre-motor and motor-symptomatic HD mutation carriers for 
suicide. 
Bird (1999) put these findings into perspective when he compared the suicide rate 
in Huntington’s disease of 138 of 100,000 persons per year with that of the general 
population (12-13 per 100,000).  Paulsen, Ferneyhough-Houth, & Nehl (2005) assessed 
  
 
suicide along with suicide completion and report much higher rates.  They indicated that 
suicidal ideation occurs in up to 50% of people with Huntington’s disease (p. 725). 
 Several studies have suggested a greater risk of suicide in Huntington disease; 
however, unique risk factors for suicide in HD are not established.  Fiedorowicz et al. 
(2011) sought to determine the risk factors for suicidal behavior in prodromal HD. Data 
was analyzed from the Neurobiological Predictors of Huntington's Disease Trial 
(PREDICT-HD) cohort study, which is a multi-site, longitudinal prospective study 
designed to identify and track markers of HD prior to the onset of classic motor 
symptoms.  Individuals were recruited from 32 sites in the US, Canada, Europe, and 
Australia (Fiedorowicz et al., 2011).  Prodromal HD can be defined as the presence of 
CAG repeat expansion prior to meeting the clinical criteria for a diagnosis of manifest 
HD (Fiedorowicz et al., 2011).  Seven hundred thirty-five cases with HD gene expansion 
without manifest symptoms and 194 non-gene-expanded controls were included in this 
analysis (Fiedorowicz et al., 2011).  A number of potential risk factors for suicidal 
behavior were assessed, including symptoms of depression, hopelessness, substance 
abuse, marital status, gender, and psychiatric history (Fiedorowicz et al., 2011).  During a 
mean of 3.7 years of prospective follow-up, 12 cases (1.6%) attempted suicide and one 
completed suicide (0.1%).  No suicides were observed among controls (Fiedorowicz et 
al., 2011).  In univariate Cox proportional hazards regression models, a history of suicide 
attempts (HR 8.5, 95% CI [2.8–26.1], p < 0.0002) and a Beck Depression Inventory II 
score greater than 13 (HR 7.2, 95% CI [2.3–22.0], p < 0.0006) were associated with 
suicidal behavior (Fiedorowicz et al., 2011).  These risk factors had independent effects 
in multivariate models.  A history of incarceration in the past 2 years was also associated 
  
 
(HR 12.5, 95% CI [2.7–56.6], p < 0.002), but uncommon (Fiedorowicz et al., 2011).  No 
further risk factors were identified.  Fiedorowicz et al. (2011) concluded a history of 
suicide attempt(s) and the presence of depression are strongly predictive of suicidal 
behavior in prodromal HD. 
 The majority of HD research has focused on cognitive and motor features of HD 
while the implications of psychiatric manifestations have received less consideration.  A 
study by Wetzel et al. (2011) examined the presence of psychiatric comorbidity and its 
involvement in suicidal ideation.  Research participants were recruited as part of an 
ongoing multi-site study at 43 Huntington Study Group sites across North America, 
Australia, and Europe (Wetzel et al., 2011).  The Unified Huntington Disease Rating 
Scale (Huntington Study Group, 1996) is a standardized clinical rating scale that assesses 
four components of HD: motor, cognitive, psychiatric, and functional.  The psychiatric 
portion of the UHDRS was primarily used in the current study (Wetzel et al., 2011).  This 
section assesses the frequency and severity of 14 psychiatric symptoms associated with 
HD, using a semi-structured interview.  The following symptoms were considered: sad 
mood, anxiety, suicidal thoughts, compulsive behavior, irritable behavior, apathy, 
delusions, and hallucinations (Wetzel et al., 2011).  For each symptom, a total score was 
obtained by multiplying the severity score (rated from 0–4) by the frequency score (rated 
from 0–4), which results in a minimum score of zero and a maximum of 16 for each 
symptom (Wetzel et al., 2011).  Five psychiatric factors, including depression/anxiety, 
suicidal thoughts, aggressivity, obsessive/compulsive behavior, and delusions, were also 
evaluated (Wetzel et al., 2011).  Hallucinations were grouped into four distinct factors 
(audiovisual, tactile, gustatory, and olfactory; Wetzel et al., 2011).  Suicidal ideation was 
  
 
measured on the psychiatric portion of the UHDRS and was scored in terms of frequency 
and severity.  Frequency scores were the following: 0 = almost never, 1 = seldom, 2 = 
sometimes, 3 = frequently, 4 = almost always (Wetzel et al., 2011).  Severity scores were 
measured similarly: zero = absent, 1 = slight, 2 = mild, 3 = moderate, 4 = severe (Wetzel 
et al., 2011).  A total suicidal ideation score was obtained by multiplying frequency by 
severity with ranges from 0 to16 (Wetzel et al., 2011).  In addition to the psychiatric 
symptoms, as measured by the UHDRS, (a)  the total motor score; (b) the total cognitive 
score; and (c) past reports of alcohol, drug, and tobacco abuse were analyzed (Wetzel et 
al., 2011). 
The Huntington Study Group collected data on over 4,000 patients with or at risk 
for HD worldwide; 18% of those reported suicidal ideation (Wetzel et al., 2011).  
Because the purpose of this study was to assess suicidal ideation in those with HD, only 
individuals with a current HD diagnosis score of 2 (probable HD) or 3 (definite HD) on 
the UHDRS were included in the current study.  A total of 3,391 individuals in the 
database met these criteria.  Of the 3,391 individuals with probable or definite 
Huntington disease, complete data was available for 1,941 individuals (Wetzel et al., 
2011).  Suicidal ideation was assessed as a categorical variable due to the skewed nature 
of the distribution.  Suicidal ideation was scored as “present” or “absent” based on the 
suicide severity and frequency item of the UHDRS (Wetzel et al., 2011).  Any 
endorsement of suicidal ideation (scores ≥ 1) was scored as present.  This assessment of 
suicidal ideation serves as the dependent measure in further analyses.  A bivariate logistic 
regression analysis was used to assess whether demographic (age, sex, years of 
education), motor symptoms, cognitive impairment (Symbol Digit Modalities Test), 
  
 
and/or psychiatric symptoms (UHDRS Depression/Anxiety, Aggression, 
Obsession/Compulsion factors as well as alcohol, illicit drug, and tobacco use history) 
would predict the presence or absence of suicidal ideation Wetzel et al., 2011. 
Bivariate logistic regression was used with presence or absence of suicidal 
ideation as the dependent variable.  The overall model was significant (χ = 377.12, df = 
11, p < 0.01; Wetzel et al., 2011).  None of the demographic, motor, or cognitive 
variables was significant predictors of presence or absence of suicidal ideation (Wetzel et 
al., 2011).  Higher UHDRS depression/anxiety (OR = 1.11, p < 0.01) and aggression (OR 
= 1.04, p < 0.01) factors were significant predictors of suicidal ideation, however (Wetzel 
et al., 2011). 
  Schoenfeld et al. (1984) presented data collected by the New England 
Huntington’s Disease Center to evaluate the suicide patterns of patients with HD. 
Histories of 149 apparently unrelated families with Huntington’s disease, involving 4,919 
individuals were collected (Schoenfeld et al., 1984).  Within the 149 family histories, 
there were 403 deceased individuals diagnosed with Huntington’s disease and 103 
individuals suspected of having HD.  Cause of death was determined for 157 of these 506 
individuals (Schoenfeld et al., 1984).  Among the 403 deceased HD patients, there were 
nine documented suicides, all of whom were male.  Of the 103 suspected HD patients, 
there were 11 documented suicides, seven males and four females (Schoenfeld et al., 
1984).  The method of suicide was ascertained for 14 of these individuals and included 
drowning (4), asphyxiation by poisonous gas (2), gunshot (1), hanging (2), jumping from 
a high place (3), drug overdose (1), and fire (1; Schoenfeld et al., 1984).  Schoenfeld et 
al. (1984) concluded the prevalence of suicide appeared four times higher among 
  
 
suspected HD patients than among the diagnosed and implied patients early in the course 
of their disease are particularly prone to suicide. 
Hubers, van Duijn, Roos, van der Mast, and Giltay (2012) used data from the 
European Huntington Disease Network (EHDN) Registry Study to evaluate suicide in the 
European Huntington’s disease population.  Their study investigated the clinical 
associations and predictors of suicide in a large European cohort of HD mutation carriers 
(Hubers et al., 2012).  The presence of suicide in the preceding month were assessed in 
2106 mutation carriers from 15 European countries, all participating in the EHDN 
Registry.  Mutation carriers were considered suicidal if the total score on the suicidal 
ideation assessment of the Unified Huntington’s Disease Rating Scale was greater than 1 
point (Hubers et al., 2012).  Associations of suicide were analyzed using multi-variate 
logistic regression analysis, and Cox regression analysis was used to determine predictors 
of suicide (Hubers et al., 2012).  Of the 1937 individuals characterized as free of suicide 
at baseline, 945 had one or more follow-up measurements.  The results of the analysis 
indicated that at baseline, 169 (8%) mutation carriers were considered suicidal.  Cross-
sectionally, the presence of anxiety, aggression, a previous suicide attempt, and 
depression were independently associated to suicide (Hubers et al., 2012).  During 
follow-up, 45 (5.5%) mutation carriers became suicidal (Hubers et al., 2012).  The 
presence of depressed mood and the use of benzodiazepines at baseline were independent 
predictors of suicide at follow-up (Hubers et al., 2012).  CAG repeat length was not a 
variable that was evaluated to determine if it were a predictor of suicide.  Although 
suicidal ideation is commonly considered to be one index of suicidal risk, no studies have 
  
 
previously examined if CAG repeat length may be a predictor of suicide.  This proposed 
research will study if a correlation exists between suicide and CAG repeat length.   
CAG Length and Clinical Presentation 
Several articles were analyzed to identify if a predictive relationship exists 
between age of onset of Huntington’s disease symptoms or clinical presentation of 
individuals based upon CAG repeat length.  Zappacosta et al. (2006) conducted a study to 
determine if psychiatric disturbances in Huntington’s disease are related to either the 
degree of cognitive or motor compromise or CAG repeat length (Zappacosta et al., 2006).  
The study included 17 male and 12 female subjects with genetically confirmed HD.  The 
outcome measures were the following: (a) the Hamilton Psychiatric and Anxiety Rating 
Scales and Brief Psychiatric Rating Scale to assess psychiatric disturbances; (b) Folstein's 
Quantified Neurological Examination to evaluate motor status; and (c) the Mini-Mental 
State Examination, Raven Progressive Matrices, Phonemic Verbal Fluency Test, Short 
Tale Test, Visual Search Test, and Benton's Visual Orientation Line Test to evaluate 
cognitive function.  The length of the CAG repeat sequence in the Huntington's gene was 
determined by quantitative polymerase chain reaction (PCR; Zappacosta et al., 2006).  
Results of the Folstein’s Quantified Neurological Examination correlated with illness 
duration and length of CAG repeat (Zappacosta et al., 2006).  Although psychiatric scores 
correlated significantly among themselves (p < 0.01), neither cognitive compromise, 
motor deterioration, nor CAG length were related to the extent of psychiatric compromise 
(Zappacosta et al., 2006).  Zappacosta et al. (2006) concluded there was no correlation 
between disease severity and psychiatric disturbances, which may indicate that 
psychiatric disorders progress nonlinearly, possibly because of differential degeneration 
  
 
of the striatal-cortical circuits.  In addition, the lack of correlation between CAG length 
and cognitive and psychiatric variables need further investigation (Zappacosta et al., 
2006). 
Unintended weight loss.  One of the hallmarks of Huntington’s disease is 
unintended weight loss, the cause of which is relatively unknown (Aziz et al., 2008).  
Aziz et al. (2008) evaluated potential causes of weight loss, including motor, cognitive, 
behavioral disturbances, and CAG repeat length (Aziz et al., 2008).  Five hundred 
eighteen patients with early Huntington’s disease were included in this study (Aziz et al., 
2008).  Aziz et al. applied mixed-effects model analyses to correlate weight changes over 
three years to CAG length, body mass index (BMI), and Unified Huntington’s Disease 
Rating Scale (UHDRS).  Results indicated that mean body mass index decreased -0.15 
units per year (p < 0.001), and subjects with higher CAG repeat numbers had a faster rate 
of weight loss (Aziz et al., 2008).  However, no single UHDRS component, including 
motor, cognitive, and behavioral scores, was independently associated with the rate of 
weight loss (Aziz et al., 2008).  Aziz et al. (2008) concluded weight loss in Huntington’s 
disease is directly linked to CAG repeat length and is likely to result from a hyper-
metabolic state.   
CAG repeats.  Ashizawa et al. (2008) evaluated parental versus maternal 
transmitted disease severity, atypical symptoms that may make initial diagnosis 
complicated, and the age of disease onset.  The objective of this study was to determine if 
there is a relationship between CAG repeat size and clinical presentation (Ashizawa et 
al., 2008).  The subjects included 36 patients with suspected HD and 12 patients with no 
relatives documented with HD (Ashizawa et al., 2008).  Five of those failed to show the 
  
 
expanded (> 37) CAG repeats and were therefore excluded from the study (Ashizawa et 
al., 2008).  Incidentally, one of these patients was later diagnosed with 
neuroacanthocytosis (Ashizawa et al., 2008).  The remaining 31 patients, including seven 
patients with atypical clinical features for HD (three without and four with family history 
of documented HD), were heterozygotes for the CAG repeat expansion (Ashizawa et al., 
2008).  The patients with atypical features presented with myopathy of unknown origin, 
low sperm count, action myoclonus, torticollis, Tourette syndrome, dystonia, and action 
tremor (Ashizawa et al., 2008).  There were large CAG repeats (50 copies) in paternally 
transmitted HD cases with early onset of 30 years or younger (Ashizawa et al., 2008).  
Data was collected using PCR for DNA analysis (Ashizawa et al., 2008).  The onset of 
Huntington’s disease was defined as the “first realization of involuntary movements, 
dementia, or psychiatric manifestation by the patient, family, and/or physician” 
(Ashizawa et al., 2008, p. 1137).  The Physical Disability Rating Scale was used to 
measure disease progression.  The results of the study indicated the following 
conclusions: patients lacking a family history of Huntington’s disease frequently showed 
no expansion of CAG repeats, the gender of the affected parent influences CAG repeat 
size, and the gender of the affected parent affects the phenotypic expression of offspring 
(Ashizawa et al., 2008).  In addition, determination of CAG repeat size has a practical 
diagnostic value in patients who lack family history of HD or in those patients with an 
atypical clinical presentation (Ashizawa et al., 2008). 
Andrew et al. (1993) conducted a study to determine if there were a relationship 
between CAG repeat length and clinical presentations of Huntington’s disease.  The 
subjects included 360 HD patients from 259 unrelated families (Andrew et al., 1993).  
  
 
The methods of the study were not specified in the abstract and full-text article was not 
available in archives.  The results of the study indicated there is a highly significant 
correlation between age of onset of symptoms and CAG repeat length (Andrew et al., 
1993).  In addition, there seems to be a correlation between age of death and the onset of 
other clinical features with CAG repeat number (Andrew et al., 1993). 
Rosenblatt et al. (1996) investigated whether the rate of clinical progression in 
HD is influenced by the size of CAG expansion.  The study included 512 subjects with a 
diagnosis of Huntington’s disease (Rosenblatt et al., 1996).  The outcome measures were 
Quantified Neurological Examination (QNE) with three sub-scales: (a)  Motor 
Impairment Scale (MIS), chorea scale, and eye movement scale; (b) Mini-Mental Status 
Examination (MMSE); (c) activities of daily living (HD-ADL), and (d) CAG repeat 
length, using PCR (Rosenblatt et al., 1996).  Included in the analysis were individuals 
with CAG lengths ranging from 36 to 97 repeats (Rosenblatt et al., 1996).  The results of 
the study indicated that CAG length was significantly associated with the rate of 
progression with regard to motor impairment, eye movement, and cognition (Rosenblatt 
et al., 1996).  There was not a significant correlation between CAG length and chorea and 
activities of daily living (Rosenblatt et al., 1996).  In addition, it was presumed that the 
shortest CAG lengths had the latest ages of onset (Rosenblatt et al., 1996). 
Theory Specific to Research Topic 
The diathesis-stress model of suicidal behavior, a psychological theory that 
attempts to explain behavior as a pre-dispositional vulnerability, together with stress 
increases the risk of suicide (Ingram & Luxton, 2005).  The diathesis, or predisposition, 
interacts with the subsequent stress response of an individual.  Stress refers to a life event 
  
 
or series of events that disrupt an individual’s psychological equilibrium and potentially 
serves as a catalyst to the development of suicidal behavior (Ingram & Luxton, 2005).  
Thus, the diathesis-stress model of suicidal behavior serves to explore how non-
biological or genetic traits (diatheses) interact with environmental influences (stressors) 
that lead to suicide (Ingram & Luxton, 2005).  Mann (1998) proposed a stress-diathesis 
model of suicidal behavior based on his findings from a clinical study of a large sample 
of patients admitted to a university psychiatric hospital.  When compared to patients 
without a history of suicide attempts, patients with a history of attempt had higher scores 
on subjective depression and suicidal ideation surveys and reported fewer reasons for 
living (Mann, 1998).  In addition, suicide attempters showed higher rates of lifetime 
aggression, impulsivity, co-morbid borderline personality disorder, substance abuse 
and/or alcoholism, family history of suicidal acts, head injury, smoking, and history of 
child abuse (Mann, 1998).  Mann concluded the risk for a suicidal act is thus determined 
not only by a psychiatric illness or stressor, but also by a diathesis exhibited by 
tendencies to experience more suicidal ideation and to be more impulsive, therefore, 
more likely to act on suicidal feelings (Mann, 1998).  Simon, Swann, Powell, Potter, 
Kreshnow, and O’Carroll (2001) conducted a case-control study of nearly lethal suicide 
attempts among people 13 to 34 years of age.  Subjects were asked, “How much time 
passed between the time you decided to complete suicide and when you actually 
attempted suicide?”  (Simon et al., 2001, pp. 49-59).  Attempts were considered 
impulsive if the respondent reported spending less than 5 minutes between the decision to 
attempt suicide and the actual attempt.  Among the 153 case subjects, (a) 24% attempted 
impulsively (< 5 minutes), (b) 24% said 5 to 19 minutes, (c) 23% said 20 to 60 minutes, 
  
 
(d) 16% said 2 to 8 hours, and (e) 13% said 1 or more days (Simon et al., 2001, pp. 49-
59).   
The purpose of this study was to determine if a correlation exists between suicide 
and CAG repeat length.  Specifically, if CAG length is a diathesis or pre-disposition for 
suicidal behavior in Huntington’s disease.  Most stress-diathesis models presume that all 
people have some level of diathesis for any given psychiatric disorder (van Herrigan, 
2012).  The point at which the individual develops a disorder depends on the degree to 
which pre-dispositional risk factors exist and the severity of stress that is experienced 
(van Heeringen, 2012).  This theory also assumes a dichotomous diathesis: either one has 
it (gene, brain pathology) or one does not have it (van Heeringen, 2012).  If the diathesis 
is absent, stress has no effect, and there is no development of a psychiatric disorder.  
When the diathesis is present, the expression of the disorder will be conditional on the 
degree of stress (van Heeringen, 2012).  The conceptualization of a diathesis as dynamic 
implies that such a diathesis is continuous rather than dichotomous.  For example, 
schema models of depression were commonly regarded as dichotomous models; if an 
individual possessed a depressogenic schema, then he or she is at risk of depression when 
events that activate this schema occur (van Heeringen, 2012).  More recent discussions of 
the schema model have, however, pointed at the possibility of a continuous character by 
describing the depressogenic nature of schemata as ranging from weak or mild to strong 
(van Heeringen, 2012).  A continuous diathesis can involve interaction between a stress 
and a diathesis that might not be static, but may change over time (van Heeringen, 2012).  
The diathesis may increase or decrease so that the amount of stress needed for the 
  
 
development of pathology may need to decrease or increase, which may explain 
differences in suicidal behavior among patients with HD (van Heeringen, 2012).  
Summary of What is Known and Unknown about the Topic 
Zappacosta et al. (1996) investigated the hypothesis that psychiatric disturbances 
in Huntington's disease are related to the degree of cognitive or motor compromise.  In 
addition, the study was conducted to determine correlations between CAG repeat length 
and psychiatric disease severity in 17 men and 12 women from 24 families affected by 
Huntington’s disease.  The following evaluations were made: (a) the Hamilton 
Psychiatric and Anxiety Rating Scales and Brief Psychiatric Rating Scale were used to 
assess psychiatric disturbances; (b) Folstein's Quantified Neurological Examination was 
used to evaluate motor status; and (c) the Mini-Mental State Examination, Raven 
Progressive Matrices, Phonemic Verbal Fluency Test, Short Tale Test, Visual Search 
Test, and Benton's Visual Orientation Line Test were used to evaluate cognitive function.  
The length of the CAG repeat sequence in the Huntington's gene was determined by 
quantitative polymerase chain reaction (Zappacosta et al., 1996).   
Cognitive test scores correlated significantly with each other; of these, results of 
the Visual Search and Short Tale tests correlated significantly with the Folstein's 
Quantified Neurological Examination score (p  = .05 and p = .03, respectively).  Results 
of the Folstein's Quantified Neurological Examination also correlated with the illness 
duration and the length of the CAG repeat.  Although psychiatric scores correlated 
significantly among themselves (p < .01), neither cognitive compromise, motor 
deterioration, nor CAG length were related to the extent of psychiatric compromise.  The 
lack of correlation between disease severity and psychiatric disturbances indicated that 
  
 
psychiatric disorders progress nonlinearly, possibly because of differential degeneration 
of the striatal-cortical circuits (Zappacosta, 1996).  According to Zappacosta et al., the 
lack of correlation between CAG length and cognitive and psychiatric variables needs 
further investigation. 
In the Zappacosta study, the Hamilton Rating Scale for Depression (HRSD) was 
utilized to measure depression.  The scale is a multiple item questionnaire designed for 
adults and is used to rate the severity of depression by probing mood, feelings of guilt, 
suicide ideation, insomnia, anxiety, weight loss, and somatic symptoms.  Initially 
considered the gold standard for rating depression in clinical research, it is now criticized 
as a test instrument for clinical practice in part because it places more emphasis on 
insomnia than on suicidal ideas and gestures (Bagby, Ryder, Sculler, & Marshall, 2004).  
Rickards et al. (2011) used data from the European Huntington’s Disease REGISTRY 
Study to examine the validity of the Beck Depression Inventory and the Hamilton Rating 
Scale for Depression in Huntington’s disease.  The outcome scores of the Hamilton rating 
Scale for Depression (Ham-D), Beck Depression Inventory (BDI), and Unified 
Huntington’s Disease Rating Scale Behavioral Section were collected from the 
REGISTRY database (Rickards et al., 2011).  All participants were divided into two 
groups (those experiencing depressed mood or no/minimal depressed mood) according to 
the item “depressed mood” of the UHDRS Behavioral section (Rickards et al., 2011).  
This item measured the frequency (score range: 0–4) and severity (score range: 0–4) of 
depressed mood that the person has been experiencing over the last month.  Lower 
numbers represented less frequent and less severe depressed mood; whereas, participants 
were classified as depressed if they scored 6 or more (Rickards et al., 2011).  Of all 
  
 
patients with a BDI score, 180 patients (21.6%) were classified as endorsing depressed 
mood according to the criterion of a score of greater or equal to 6 on the depressed mood 
item of the UHDRS Behavioral section.  Of all patients with a Ham-D score, 175 patients 
(22.8%) were classified as endorsing depressed mood, according to the criterion of a 
score of greater or equal to 6 on the depressed mood item of the UHDRS Behavioral 
section (Rickards et al., 2011).  The concept of “depression” within the setting of a 
neurological disorder, such as HD, is problematic for two main reasons.  The first reason 
is the symptoms of HD overlap with those of major depressive disorder.  For instance, 
weight loss is a common symptom of HD regardless of mood status (Rickards et al., 
2011).  The second reason is that a depressive syndrome in patients with HD may be 
different from “major depressive disorder” because the etiology is different (Rickards et 
al., 2011).  Rickards et al. discovered that apart from depressed mood, the best 
discriminators between HD patients endorsing depressed mood and those with no or 
minimal depressed mood were related to loss of interest, guilt, and suicide.  Vegetative 
symptoms related to sleep and appetite were poor discriminators as were behaviors such 
as agitation and irritability (Rickards et al., 2011).   
 In contrast, the Unified Huntington’s Disease Rating Scale was developed by 
members of the Huntington Study Group in the early 1990s to provide a comprehensive 
and reliable instrument to assess the clinical features of HD.  The UHDRS was tested by 
Kieburtz, Penney, Como, Ranen, and Schoulsson (1996) to determine reliability and 
consistency of the rating scale.  Data from the final version of the UHDRS have been 
collected prospectively on 489 patients with manifest HD from 20 sites in North America 
and Europe (Kieburtz et al., 1996).  Of this group, (a) 229 were men (46.8%), (b) 227 
  
 
were women (46.4%), and (c) the gender of 33 (6.7%) was unknown.  Four hundred and 
twenty-six patients were (a) White (87.1%), (b) 15 Black (3.1%), and (c) race was 
unknown in 48 (9.8%).  In terms of inheritance, (a) 190 patients (38.9%) inherited HD 
from their mothers, (b) 211 inherited HD from their fathers (43.1%), and (c) the affected 
parent was unknown in 88 (18.0%; Kieburtz et al.,1996).  
The final version of the UHDRS has four components, which assessed motor 
function, cognition, behavior, and functional capabilities.  The motor section of the 
UHDRS assessed motor features of HD with standardized ratings of oculomotor function, 
dysarthria, chorea, dystonia, gait, and postural stability (Kieburtz et al., 1996).  The total 
motor impairment scores were the sum of all the individual motor ratings with higher 
scores indicating more severe motor impairment than lower scores (Kieburtz et al., 1996).  
The cognitive component was assessed by a phonetic verbal fluency test, Symbol Digit 
Modalities Test, and the Stroop Interference Test (Kieburtz et al., 1996).  Higher scores 
indicated better cognitive performance.  The behavioral assessment measured the 
frequency and severity of symptoms related to affect, thought content, and coping styles.  
The total behavior score was the sum of all responses; however, this score may have less 
usefulness than the individual subscale scores for mood, behavior, psychosis, and 
obsessiveness, which were created by summing the responses to the corresponding 
questions (Kieburtz et al., 1996).  Higher scores on the behavior assessments indicated a 
more severe disturbance than lower scores (Kieburtz et al., 1996).  The functional 
assessments included the Huntington’s Disease Functional Capacity Scale (HDFCS), the 
Independence scale, and a checklist of common daily tasks (Kieburtz et al., 1996).  The 
  
 
independence scale was rated from 0 to 100.  Higher scores on the function scales 
indicated better functioning than lower scores (Kieburtz et al., 1996). 
Cronbach’s alpha analyses were used to examine the internal consistency of the 
motor, cognitive, behavioral, and functional checklist components of the UHDRS 
(Kieburtz et al., 1996).  In addition, Spearman rank order correlation coefficients were 
calculated to compare the total motor score, each cognitive test, the behavior score and 
each subscale, and the three functional scores (Kieburtz et al., 1996).  The reliability of 
the motor component of the UHDRS was examined among three clinicians who were 
experienced with the evaluation of patients with HD (Kieburtz et al., 1996).  Twenty-four 
patients were each rated by two of the three clinicians with the clinicians evaluating the 
patients independently.  The inter-rater reliability of the total motor scores and of the 
chorea and dystonia scores was assessed by intra-class correlation (Kieburtz et al., 1996). 
Kieburtz et al. found a high degree of internal consistency among the motor, 
behavioral, cognitive, and functional components of the UHDRS.  Cronbach's alpha 
values were (a) 0.95 for the motor scale, (b) 0.90 for the cognitive tests, (c) 0.83 for the 
behavioral scale, and (c) 0.95 for the functional checklist (Kieburtz et al., 1996).  In 
addition, the UHDRS assessed relevant clinical domains of HD and was designed for 
repeated administration during clinical research studies (Kieburtz et al., 1996).  
Correlational analyses showed that four components of the UHDRS were highly inter-
correlated with the exception of the total behavioral score, which did not correlate with 
any of the other assessments (Kieburtz et al., 1996).  The 24 patients in the reliability 
study included 14 men and 10 women with an average age of 48.0 16.4 (mean SD) and 
duration of HD for 9.0 5.5 years (Kieburtz et al., 1996).  TFC scores were 8.0 3.4 with a 
  
 
range of 3 to 13.  The intra-class correlation coefficient was (a) 0.94 for the total motor 
score, (b) 0.82 for the chorea score, and (c) 0.62 for the dystonia score (Kieburtz et al., 
1996). 
The UHDRS utilized several instruments and rating scales to assess various 
features of HD, including the quantitated neurological examination, HD functional 
capacity scale, HD motor rating scale, the physical disability and independence scales, 
Marsden and Quinn’s chorea scale, HD activities of daily living scale, and behavioral 
assessment (Kieburtz et al., 1996).  The UHDRS behavioral assessment included rating 
the severity and frequency of suicidal thoughts (life is not worth living, has suicidal 
thoughts, active suicidal intent, and preparation for the act; Kieburtz et al., 1996).   
Two limitations were identified in the Zappacosta et al. study (1996) that should 
be addressed in order to determine if a predictive relationship exists among CAG repeat 
and suicide.  The first limitation was the size of the study.  A relatively small sample size 
of 17 men and 12 women from 24 families affected by Huntington’s disease were 
included.  In contrast, the COHORT database provided a larger sample size, including 
2864 affected in individuals and normal controls.  The second limitation was the 
measurement tool used to assess mood.  The Hamilton rating Scale for Depression was 
designed primarily for adults and is used to rate the severity of depression by probing 
mood, feelings of guilt, suicide ideation, insomnia, anxiety, weight loss, and somatic 
symptoms.  The scale is used primarily as an assessment of depression severity rather 
than suicide risk.  Whereas, the Unified Huntington’s Disease Rating Scale Behavioral 
Assessment has been shown to be a reliable and consistent measure of mood and suicide 
(Kieburtz et al., 1996).  
  
 
Contributions 
The purpose of this study was to determine if CAG repeat length correlates with 
suicide in Huntington’s disease.  If a positive relationship exists, individuals with larger 
CAG length expansions may require additional testing, intervention, and psychotherapy 
for suicide prevention than an individual with a shorter CAG length.  Individuals 
diagnosed or at risk for Huntington’s disease have a greater suicide rate than the general 
population, but is this increased risk due to psychological and environmental factors 
alone, or can there be a genetic component that increases risk?  Numerous studies have 
shown that there is an inverse relationship between age at onset of disease and CAG 
repeat length (Brinkman et al, 2007); however, there are no previous studies that have 
evaluated if CAG length can be associated with suicide specifically. 
 If a direct relationship between CAG length and suicide exists, individuals with 
greater CAG expansions should be monitored closely for suicidal ideation and changes in 
mood.  Psychological support is critical when HD is complicated by depression and 
suicidal thoughts (Paulsen et al., 2005).  Psychological help and social work planning can 
be adapted based upon the stage of the disease (Walker, 2007).  Different phases of the 
disease require varying levels of assistance from psychiatrists, neurologists, social 
workers, dieticians, speech and occupational therapists, dental hygienists, and clinical 
psychologists (Paulsen et all, 2005).  Several protective factors for suicide can be 
implemented by the patient, family, and health care provider, which may include (a) 
ensuring effective mental health care is offered to the individual; (b) establishing positive 
connections to family, peers, and community; and (c) establishing programs to teach 
individuals the skills to recognize and address stressors.  Protective factors may reduce 
  
 
suicide risk by helping individuals with HD to cope with negative life events and 
recognize when they need to reach out to others for help. 
Summary 
 Suicidal behavior can include completed suicide, suicide attempts, and suicidal 
ideation. Individuals with Huntington’s disease often develop significant psychological 
disease, including personality change, psychosis, depression, hostility, impulsivity, 
anxiety, aggression, and suicidality (Rosenblatt et al., 2007).  Suicide and suicidal 
ideation are more common in persons with Huntington’s disease than the general 
population, but the incidence rates may change with disease course and predictive testing 
results (Almqvist, Bloch, Brinkman, Craufurd, & Hayden, 1999).  Several studies have 
investigated the prevalence, clinical association, and predictors of suicide in HD. To 
summarize, Almqvist et al. (1999) identified an increased risk of a suicidal event 
(ideation, attempt, or completion) occurred in individuals with a psychiatric history less 
than or equal to five years prior to testing and had an unemployed status. Hubers et al. 
(2012) studied the association and predictors of suicidal behavior and discovered that 
depressed mood was the only independent predictor of suicide after long-term follow-up.  
This theory was supported by Fiedorowicz et al. (2011) who concluded a history of 
suicide attempt(s) and the presence of depression were strongly predictive of suicidal 
behavior in prodromal Huntington’s disease. No studies have been previously completed 
which evaluated the correlation between CAG repeat length and suicidality. If a 
predictive relationship exists, CAG length may be a future screening tool to assess 
suicidality and suicide risk. 
 
  
 
Chapter 3 
Methodology 
Research Methods and Procedures 
The Cooperative Huntington Observational Research Trial is an observational 
study designed to collect phenotypic data and biological samples from individuals with 
HD and their family members.  A case-control study, using the COHORT Study de-
identified database, will be conducted to determine if there is a correlation between 
suicide and CAG length.  The COHORT database includes clinical assessments and 
genetic testing from 2,318 individuals collected by the Huntington Study Group over a 5-
year period of time from 2005 to 2010 (HSG, 2011).  The institutional review board of 
the University of Rochester and each site approved the protocol.  All study participants 
were provided written informed consent or, if unable to consent, had an authorized 
representative provide consent on their behalf.  Participants agreed to baseline and annual 
evaluations for an indefinite time period with no predetermined limit on the sample size.  
To protect the confidentiality and data of participants, all were assigned a unique 
identification number without identifying information (HSG, 2011). 
Sample 
Of the 2,318 individuals, 1,985 (85.6%) were classified into six analysis groups.  
Three groups had expanded CAG alleles (36 repeats or more): (a) individuals with 
clinically diagnosed HD (n = 930), (b) clinically unaffected first-degree relatives who had 
previously pursued (n = 248), or (c) not pursued (n = 112) predictive DNA testing.  Three 
groups lacked expanded alleles: (a) first-degree relatives who had previously pursued (n 
= 41), or (b) not pursued (n = 224) genetic testing, and (c) spouses and caregivers (n = 
  
 
430).  The Huntingtin CAG repeat size was determined by polymerase chain reaction 
amplification, using genomic DNA extracted from blood and, if provided, 
lymphoblastoid cell lines.  All genotyping was performed at a single site (Center for 
Human Genetic Research, Massachusetts General Hospital, Boston, Massachusetts).  
Alleles with 36 or more repeats were considered expanded.  Individual genotypes 
remained anonymous and were not communicated to any party (HSG, 2011). 
The 1985 participants in this analysis were primarily female (56.3%), had 
completed at least 12 years of education at the time of enrollment (90.0%), but were not 
currently employed in the labor force (55.3%).  At baseline, 94 (4.7%) of the 1,985 
participants reported at least one prior suicide attempt.  Individuals with clinically 
diagnosed HD were more likely to have attempted suicide (7.1%) than caregivers or 
spouses (1.2%; p = 0.001) and all other study participants (2.7%; p = 0.001).  The most 
commonly used medications among those with clinically diagnosed HD were 
antidepressants (32.4%), multivitamins (27.4%), and anti-psychotics (24.5%). For all 
other groups, commonly used medications were multivitamins (27.4%), lipid-modifying 
agents (18.9%), and anti-depressants (11.5%; Dorsey, 2012). 
The data collected included the following: demographics, family history, physical 
and psychological evaluations, UHDRS scores, genetic testing, and age of onset and 
death if applicable (HSG, 2011).  COHORT participants completed a medical and 
neurological evaluation each year for up to 5 years.  This evaluation included 
standardized assessments of movement, thinking, memory, ability to perform daily 
activities, and behavior (HSG, 2011).  The COHORT study involved (a) a baseline visit, 
comprising an assessment with the Mini-Mental State Examination; (b) a neurological 
  
 
and physical examination, including body mass index; and (c) the Unified Huntington's 
Disease Rating Scale 99 (UHDRS 99), conducted by trained study personnel.  The 
UHDRS 99 evaluated four domains, consisting of motor function, cognition, behavior, 
and functional capacity.  Further analysis compared individual items from the motor and 
behavioral sections of the UHDRS.  These items are scored on a 0 to 4 point ordinal 
scale, with 0 representing no impairment and 1 to 4 representing increasing levels of 
impairment.  The behavioral assessment evaluated the following components: sad/mood, 
low self-esteem/guilt, anxiety, suicidal thoughts, disruptive or aggressive behavior, 
irritable behavior, obsessions, compulsions, delusions, and hallucinations.  Individuals 
reporting scores above a pre-specified threshold for depressed mood or suicidal ideation 
were referred to a mental health professional (Dorsey, 2012). 
Through December 31, 2009, one completed suicide in an individual with 
clinically diagnosed HD and 11 suicide attempts (nine in individuals with clinically 
diagnosed HD) occurred.  The individual who committed suicide had reported a prior 
history of depression and multiple previous suicide attempts.  For the 11 participants who 
attempted suicide, nine (82%) were female, the mean age was 43.4 (range 26–55), seven 
(64%) had reported a prior history of depression, and four (36%) had reported a history of 
at least one previous suicide attempt.  Suicides and suicide attempts were prospectively 
assessed and reported within three working days after a research site became aware of the 
event.  To promote the safety of participants, a clinical monitor and an independent event 
monitoring committee evaluated reportable events, including suicides, suicide attempts, 
deaths other than suicides, and premature withdrawals. 
  
 
To determine if there is a correlation between CAG length and suicide, focus 
would be placed on the suicidal thought assessment, which evaluated suicidal thoughts, 
suicidal intention, and preparation for the act of suicide.  In a secondary analysis of 
COHORT, data pertaining to the Unified Huntington’s Disease Rating Scale behavioral 
assessment and death records will be evaluated to determine if there is a predictive 
relationship between CAG repeat length and suicidality.  A correlation analysis will be 
made to determine of a predictive relationship exists between these two variables.   
Data Analysis Plan 
Demographic Information 
 Data will be entered into SPSS version 22.0 for Windows.  Descriptive 
statistics will be conducted to describe the sample demographics as well as any research 
variables to be used in the analyses.  Frequencies and percentages will be calculated for 
any categorical variables of interest, such as gender or ethnicity.  Means and standard 
deviations will be calculated for any continuous variables of interest, such as age 
(Howell, 2010). 
Pre-Analysis Data Screening 
 Data will be screened for accuracy, missing data, and outliers or extreme 
cases.  Descriptive statistics and frequency distributions will be conducted to determine 
that responses are within the possible range of values and data are not distorted by 
outliers.  The presence of univariate outliers will be tested by examination of 
standardized values.  Standardized values will be created for each scale level research 
variable and examined for values that fall above 3.29 and those which fall below -3.29, 
which indicate outliers (Tabachnick & Fidell, 2012).  Cases with missing data will also 
  
 
be examined for non-random patterns.  Participants with large portions of non-random 
missing data will be excluded. 
Research Question One 
Does CAG repeat length significantly predict the frequency of suicidal ideation, 
when controlling for depression, substance abuse history, and use of benzodiazepines? 
H01: CAG repeat length does not significantly predict the frequency of suicidal 
ideation, when controlling for depression, substance abuse history, and use of 
benzodiazepines. 
Ha1: CAG repeat length does significantly predict the frequency of suicidal 
ideation, when controlling for depression, substance abuse history, and use of 
benzodiazepines. 
To address research question one, ordinal logistic regression will be conducted.  
Ordinal logistic regression is appropriate when the goal of research is to assess if a set of 
dichotomous or interval-level independent variables predict an ordinal dependent variable 
(Tabachnick & Fidell, 2012).  In the proposed analysis, CAG repeat length of 
Huntington’s disease sufferers will be the independent, or predictor variable.  Depression, 
substance abuse history and use of benzodiazepines will be covariates, and responses to 
the UHDRS survey items pertaining to the frequency of suicidal ideation (“feels life is 
not worth living”, “has suicidal thoughts”) will form the dependent variable.  CAG length 
will represent the amount of CAG repeats on the short arm of chromosome 4, and 
suicidal ideation frequency will be representative of responses to the UHDRS survey 
items pertaining to the frequency of a patient’s suicidal ideation.  Suicidal ideation 
  
 
frequency will have possible scores between zero and four, and the number of CAG 
repeats does not have a definitive upper bound. 
Standard multiple regression – the enter method – will be used. The standard 
method enters all independent variables (predictors) simultaneously into the model.  
Unless theory sufficiently supports the method of entry, the standard multiple regression 
is the appropriate method of entry.  Variables will be evaluated based on what each add 
to the prediction of the dependent variable that is different from the predictability 
provided by the other predictors (Tabachnick & Fidell, 2012).  The χ2 test will be used to 
assess whether the set of independent variables collectively predicts the dependent 
variable.  The pseudo R2, will be reported and used to determine how well variations in 
the dependent variable can be accounted for by the set of independent variables.  The 
Wald statistic will be used to determine the significance of each predictor. 
Unlike non-logit linear regressions, the logistic regression does not have the same 
assumptions of normality and homoscedasticity.  Instead, the logistic regression only 
requires an adequate sample size.  The typical rule of thumb for a logistic regression is 
20-30 total participants per predictor variable (Peduzzi et al. 1996; LeBlanc and 
Fitzgerald, 2000).  Thus, at minimum, there should be at least 80-120 participants since 
there are at least 4 predictors (CAG, drug abuse, depression, benzodiazepine use).  The 
other assumption of the ordinal regression is the assumption of parallel slopes.  Parallel 
slopes assumes that the estimate for the slope is the same across all categories of the 
dependent variable.  Thus as the predictor variable increases by one unit, the likelihood 
for the participant to be in one higher unit in the ordered dependent variable increases 
linearly.  This assumption is tested via the chi square test of parallel slopes.  If the 
  
 
assumption of parallel slopes fails, then a multinomial logistic regression will be 
conducted instead.  
Research Question Two 
Does CAG repeat length significantly predict the severity of suicidal ideation, 
when controlling for depression, substance abuse history, and use of benzodiazepines? 
H02: CAG repeat length does not significantly predict the severity of suicide 
ideation, when controlling for depression, substance abuse history, and use of 
benzodiazepines. 
Ha2: CAG repeat length does significantly predict the severity of social ideation, 
when controlling for depression, substance abuse history, and use of benzodiazepines. 
 
To address research question two, ordinal logistic regression will be conducted.  
In the proposed analysis, CAG repeat length of Huntington’s disease sufferers will be the 
independent, or predictor variable.  Depression, substance abuse history and use of 
benzodiazepines will be covariates, and responses to the UHDRS survey items pertaining 
to the severity of suicidal ideation (“feels life is not worth living”, “has suicidal 
thoughts”) will form the dependent variable.  CAG length will represent the amount of 
CAG repeats on the short arm of chromosome 4, and suicidal ideation severity will be 
representative of the responses to the UHDRS survey items pertaining to the severity of a 
patient’s suicidal ideation.  Suicidal ideation frequency will have possible scores between 
zero and four, and the number of CAG repeats does not have a definitive upper bound. 
Standard multiple regression – the enter method – will be used. The standard 
method enters all independent variables (predictors) simultaneously into the model.  
  
 
Unless theory sufficiently supports the method of entry, the standard multiple regression 
is the appropriate method of entry.  Variables will be evaluated based on what each add 
to the prediction of the dependent variable that is different from the predictability 
provided by the other predictors (Tabachnick & Fidell, 2012).  The χ2 test will be used to 
assess whether the set of independent variables collectively predicts the dependent 
variable.  The pseudo R2, will be reported and used to determine how well variations in 
the dependent variable can be accounted for by the set of independent variables.  The 
Wald statistic will be used to determine the significance of each predictor. 
Prior to analysis, the assumption of parallel slopes will be assessed.  This 
assumption will be tested via the chi square test of parallel slopes.  If the assumption of 
parallel slopes fails, then a multinomial logistic regression will be conducted instead.  
 
Research Question Three 
Does the UHDRS behavioral assessment accurately represent suicidal behavior of 
Huntington’s disease patients? 
To address research question three, descriptive statistics will be conducted on 
responses to the UHDRS for the sample.  Means and standard deviations will be 
calculated for the suicidal behavior subscales of the UHDRS assessment to provide 
average responses, while frequencies and percentages will indicate how many 
participants were ranked as “absent,” “slight / questionable,” “mild,” “moderate,” or 
“severe” for the severity and frequency of each suicidal behavior.  These statistics will 
provide a summary of the responses for the sample which may then be compared to 
previous literature concerning suicidal behavior.  If the sample matches roughly with 
  
 
previous literature, the UHDRS can be said to accurately represent suicidal behavior for 
the subjects enrolled in the COHORT study. 
Sample Size Justification 
The proposed study will utilize two ordinal logistic regressions.  Because these 
were the only inferential analyses, a minimum sample size to achieve empirical validity 
was calculated for these analyses.  The typical rule of thumb for a logistic regression is 
20-30 total participants per predictor variable (Peduzzi et al. 1996; LeBlanc and 
Fitzgerald, 2000).  Thus, at minimum, there should be at least 80-120 participants since 
there are at least 4 predictors (CAG, drug abuse, depression, benzodiazepine use). 
Resource Requirements   
The COHORT database includes clinical assessments and genetic testing from 
2,318 individuals collected by the Huntington Study Group over a 5-year period of time 
from 2005 to 2010 (HSG, 2011).  All COHORT data to be shared among researchers had 
all identifying information removed.  In order to gain access to the de-identified database, 
a research proposal was submitted and reviewed by the Huntington Study Group.  Upon 
approval of the research proposal, a clinical data disclosure agreement was executed 
between the investigator and the Huntington Study Group.  After the contract was 
finalized, a CD-ROM using a password-protected zip drive was shipped via Federal 
Express (HSG, 2011).  Included in the CD-ROM were the de-identification plan, data 
dictionary, family history data dictionary, genotypic data, and family history data (HSG, 
2011).  The resources required for access to the COHORT de-identified database after 
approval from the Huntington’s Study Group included a computer with WinZip 
installation and Excel software. 
  
 
 
Reliability and Validity 
The most common confounding variables of case-control studies are sampling 
bias and observation or recall bias (Hulley, 2007).  The case (pre-manifest HD 
individuals) and the control groups may each be biased (Hulley, 2007).  In this particular 
study, participants of COHORT were voluntarily enrolled at a specialized HD clinic or 
research center in North America or Australia.  It is also important to evaluate if there 
were bias among the normal controls.  In this instance, the control group of the COHORT 
study was primarily family members of Huntington’s disease participants.  Additionally, 
retrospective studies have a greater chance of recall errors or incomplete information 
(Blessing, 2006).  Retrospective recall bias can be minimized by using archived data for 
other purposes before the studied outcome had occurred (Blessing, 2006).  A limitation is 
the reliability or availability of previously collected data (Polit, 2008).    
 Sampling bias can be minimized by obtaining a random sample of the patients 
with the disease as well as the controls (Hulley, 2007).  To enable the controls to 
accurately represent the same population as the cases, one of the following four 
techniques should be utilized: convenience sampling, matching, using more than one 
control group, and/or using a population-based sample (Hulley, 2007).  A convenience 
sample occurs when the control and cases are sampled from the same population, such as 
the same health care clinic (Polit, 2008).  A convenience sample is relatively easy to 
obtain, but may reduce the external validity of the study (Polit, 2008).  Matching is 
another technique utilized to accurately represent the population (Hulley, 2007).  The 
advantage of matching is that it allows for a smaller sample size for any given effect to be 
  
 
statistically significant (Hulley, 2007).  In contrast, “over-matching” may cause the true 
differences to be underestimated (Polit, 2008).  A research conclusion may be more 
robust if more than one control group is utilized (Blessing, 2006).  If the study 
demonstrates there is a significant difference between the cases and the controls, 
additional sampled control groups will enhance the final results (Hulley, 2007).  Lastly, 
using a random sample of patients with disease and controls from the population can 
minimize sampling bias (Hulley, 2007). 
 Selection bias can occur when entry into a study is influenced by investigator 
knowledge of the exposure status of potential subjects (Blessing, 2006).  This type of bias 
is more common in case-control study designs because the disease state is already known 
before entry into the study (Blessing, 2006).  Observation or information bias is common 
when assessing disease outcomes in follow-up studies and exposure assessment in case-
control studies (Polit, 2008).  In case-control study designs, the disease state has already 
occurred at the initiation of the study and information is sought about exposures in the 
past (Hulley, 2007).  Bias can occur from either the investigator’s or the subject’s attitude 
towards the study (Polit, 2008).  Lastly, confounding exists when the relationship 
between the exposure and the disease is a result of a mixture of the effect of the exposure 
under evaluation and other extraneous factors (Polit, 2008). 
Limitations 
Although COHORT has tremendous value and potential, it has several limitations.  
The study population, overwhelmingly White, relatively highly educated, and currently 
centered in three countries, may not be representative of the broader HD population (Ha 
et al., 2012).  Study participants were enrolled primarily at academic research centers, 
  
 
which might limit the generalizability to individuals lacking access to these clinics, 
including those residing in nursing facilities (Ha et al., 2012). 
Timeline 
 An estimate has been made for the timeline for this project.  The proposed 
timeline for this study is 4 months for data analysis and interpretation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Chapter 4 
Results 
Introduction 
The Cooperative Huntington Observational Research Trial (COHORT) is an 
observational study designed to collect phenotypic data and biological samples from 
individuals with HD and their family members.  A case-control study, using the 
COHORT Study de-identified database, was conducted to determine if a correlation 
between suicide and CAG length exists.  The COHORT database includes clinical 
assessments and genetic testing from 2,318 individuals collected by the Huntington Study 
Group over a 5-year period of time from 2005 to 2010 (HSG, 2011).  The institutional 
review board of the University of Rochester and each clinical research site approved the 
protocol.  All study participants were provided written informed consent or, if unable to 
consent, had an authorized representative provide consent on their behalf.  Participants 
agreed to baseline and annual evaluations for an indefinite time period with no 
predetermined limit on the sample size.  Institutional Review Board approval from Nova 
Southeastern University was obtained prior to any study related procedures conducted. 
Descriptive Statistics 
 Responses were collected from 163 participants.  142 participants (87%) recorded 
a response of 0 for drug abuse, two participants (1%) recorded a response of 1 for drug 
abuse, and 19 participants (12%) recorded a response of 2 for drug abuse.  Forty-eight 
participants (29%) recorded a response of 0 for depression and 115 participants (71%) 
recorded a response of 1 for depression.  One hundred and eighteen participants (72%) 
responded “No” to Benzodiazepine use and 45 participants (28%) responded “Yes” to 
  
 
Benzodiazepine use.  Results for the occurrence of each confounding variable can be 
found in Table 1. 
Table 1 
Frequencies for each Control Variable in the Sample 
Response n % 
    
Drug use   
 No 142 87 
 Yes, active 2 1 
 Yes, not active 19 12 
History of depression   
 No depression 48 29 
 Depression 115 71 
Benzodiazepine use   
 No 118 72 
 Yes 45 28 
 
 The mean amount for CAG repeat length in the sample was 43.69 (SD = 4.09).  
Results for the descriptive statistics for CAG repeat length can be found in Table 2.  
Table 2 
Descriptive Statistics for CAG Repeat Length 
Variable Minimum Maximum Mean Std. Deviation 
     
CAG Repeat 
Length 
38 59 43.69 4.09 
 
Research Question One 
Does CAG repeat length significantly predict the frequency of suicidal ideation, when 
controlling for depression, substance abuse history, and use of benzodiazepines? 
H01: CAG repeat length does not significantly predict the frequency of suicidal ideation, 
when controlling for depression, substance abuse history, and use of benzodiazepines. 
  
 
Ha1: CAG repeat length does significantly predict the frequency of suicidal ideation, 
when controlling for depression, substance abuse history, and use of benzodiazepines. 
 An ordinal logistic regression was conducted to assess if CAG repeat length 
predicted frequency of suicidal ideation.  Prior to analysis, the assumption of proportional 
odds was assessed by using the test of parallel lines.  Results of the test of parallel lines 
were not significant (p = .993) and the assumption was met.  The results of the ordinal 
logistic regression showed significance, χ2(4) = 14.17, p = .007, suggesting that CAG 
predicted frequency of suicidal ideation.  Since the model was significant, the individual 
predictors were examined.  CAG repeat length was a significant predictor of frequency of 
suicidal ideation, p = .010, suggesting that as CAG repeat length increased, the likelihood 
of being in a higher category of frequency of suicidal ideation also tended to increase.  
Depression was also found to be a significant predictor of frequency of suicidal ideation, 
p = .004, suggesting that participants with depression had a higher likelihood of being in 
a higher category of frequency of suicidal ideation.  Results of the ordinal logistic 
regression are presented in Table 3.  
Table 3 
Ordinal Logistic Regression for CAG Repeat Lengths, Drug Abuse, Depression, and 
Benzodiazepine Use Predicting Frequency of Suicidal Ideation 
 
Variable 
 
B 
 
SE 
 
Z 
 
p 
95% Confidence Interval 
Lower 
Bound 
Upper 
Bound 
       
Drug Abuse -.30 0.23 -1.28 .200 0.47 1.17 
Depression 1.03 0.36 2.88 .004 1.39 5.69 
Benzodiazepine Use -
0.03 
0.34 -0.08 .934 0.50 1.89 
CAG Repeat Length 0.09 0.04 2.59 .010 1.02 1.18 
 
 
  
 
Research Question Two 
Does CAG repeat length significantly predict the severity of suicidal ideation, when 
controlling for depression, substance abuse history, and use of benzodiazepines? 
H02: CAG repeat length does not significantly predict the severity of suicide ideation, 
when controlling for depression, substance abuse history, and use of benzodiazepines. 
Ha2: CAG repeat length does significantly predict the severity of social ideation, when 
controlling for depression, substance abuse history, and use of benzodiazepines. 
 An ordinal logistic regression was conducted to assess if CAG repeat length 
predicted severity of suicidal ideation.  Prior to analysis, the assumption of proportional 
odds was assessed by using the test of parallel lines.  Results of the test of parallel lines 
were not significant (p = .107) and the assumption was met. The results of the ordinal 
logistic regression showed significance, χ2(4) = 11.83, p = .019, suggesting that CAG 
repeat length predicted severity of suicidal ideation.  Since the model was significant, the 
individual predictors were examined.  The covariate depression was a significant 
predictor of severity of suicidal ideation, p = .003, suggesting that as depression 
increased, the likelihood of being in a higher category of severity of suicidal ideation also 
tended to increase.  Thus, when the effect of depression was taken into account, there was 
no significant relationship between CAG repeat length and the severity of suicidal 
ideation.  Results of the ordinal logistic regression are presented in Table 4.   
Table 4 
Ordinal Logistic Regression for CAG Repeat Lengths, Drug Abuse, Depression, and 
Benzodiazepine Use Predicting Severity of Suicidal Ideation 
 
Variable 
 
B 
 
SE 
 
Z 
 
p 
95% Confidence Interval 
Lower 
Bound 
Upper 
Bound 
       
  
 
Drug Abuse -0.27 0.24 -1.16 .247 0.48 1.21 
Depression 1.02 0.35 2.95 .003 1.41 5.46 
Benzodiazepine Use -0.38 0.34 -1.11 .267 0.35 1.34 
CAG Repeat Length 0.06 0.04 1.73 .084 0.99 1.15 
 
Research Question Three 
Does the Unified Huntington’s Disease Rating Scale (UHDRS) behavioral assessment 
accurately represent suicidal behavior of Huntington’s disease patients? 
H03: The Unified Huntington’s Disease Rating Scale (UHDRS) behavioral assessment 
does not accurately represent suicidal behavior of Huntington’s disease patients. 
Ha3: The Unified Huntington’s Disease Rating Scale (UHDRS) behavioral assessment 
does accurately represent suicidal behavior of Huntington’s disease patients. 
To address research question three, responses to the UHDRS behavioral 
assessment were examined.  Suicidal ideation was measured on the psychiatric portion of 
the UHDRS and was scored in terms of frequency and severity. Frequency scores were: 
0= almost never, 1= seldom, 3= sometimes, 4= almost always. Severity scores were 
measured similarly: 0= almost never, 1= slight, 2= mild, 3= moderate, 4= severe.  
Frequencies and percentages were calculated along with the proposed means and 
standard deviations to allow a comprehensive view of these responses.  The most 
commonly cited frequency of suicidal ideation was Seldom thinking about suicide – less 
than once a month, with 88 (54%) patients reported as falling into this category.  The 
least commonly cited frequency of suicidal ideation was Not thinking about suicide or 
self-harm, with 5 (3%) patients who were reported as falling into this category.  The 
average frequency rating for the entire sample was 1.72 (SD = 1.03). 
  
 
 The most commonly cited severity of suicidal ideation was No thoughts at current 
time, but person talks about suicide as a potential option, with 88 (54%) of patients 
reported as falling into this category.  The least commonly cited severity of suicidal 
ideation was Has a plan and is actively preparing, with 2 (1%) of patients reported as 
falling into this category.  The average severity rating for the sample was 1.04 (SD = 
0.84).  Descriptive statistics for the frequencies of each response are presented in Table 5. 
 This analysis does not fully answer whether the Unified Huntington’s Disease 
Rating Scale (UHDRS) behavioral assessment accurately represents suicidal behavior of 
Huntington’s disease patients.  Current literature cites the incidence and prevalence of 
suicide and the frequency of suicidality in Huntington’s disease, but not specifically the 
severity of suicidal behavior. Wetzel et al. (2011) evaluated the role of co-morbidity in 
suicidal ideation in Huntington’s disease.  Suicidal ideation was examined in 1,941 HD 
patients enrolled in the Huntington Study Group (Wetzel, 2011).  Of those, the frequency 
of suicidal ideation was 19% (N= 369).  With regard to suicidality, greater than one-
fourth of participants (26.5%) acknowledged a history of suicidal ideation, while 9.5% 
reported a history of at least one suicide attempt (Wetzel, 2011).  Nineteen participants 
(N=369) endorsed current suicidal ideation (Wetzel, 2011).  In comparison, 46% of the 
cohort used in this analysis reported suicidal ideation at least once a month.  In addition, 
75% of participants are either actively planning a suicide attempt or consider suicide to 
be an option in the future. Only 25% of participants admit to having no suicidal ideation. 
 Kieburtz et al. (1996) evaluated the reliability and consistency of the Unified 
Huntington’s Disease Rating Scale (UHDRS).  Neurologists, psychiatrists, 
neuropsychologists, and other healthcare professionals participated in drafting the final 
  
 
version of the UHDRS (Kieburtz, 1996).  Data from the final version of the UHDRS was 
prospectively collected on 489 patients with manifest HD from 20 sites in North America 
and Europe (Kieburtz, 1996). The final version of the UHDRS contained 4 components 
including motor function, cognition, behavioral, and functional abilities. Specifically, the 
behavioral assessment measures the frequency and severity of symptoms related to affect, 
thought content, and coping styles (Kieburtz, 1996).  The total behavior score is the sum 
of all responses; however this total score may have less clinical applicability than the 
individual subscale scores for mood behavior, psychosis, and obsessiveness which are 
created by summing the corresponding questions (Kieburtz, 1996). The clinician is 
responsible for providing a clinical impression as to whether the patient, at the time of the 
evaluation, has clinical evidence of confusion, dementia, suicidality, or depression 
according to preset definitions in the examination guidelines (Kieburtz, 1996).   
 The results this analysis by Kieburtz et al. (1996) indicated there was a high 
degree of consistency in each of the four components of the UHDRS.  Correlation 
analyses showed that four components of the UHDRS were highly inter-correlated, with 
the exception of the total behavioral score which did not correlate with any of the other 
assessments (Kieburtz, 1996).  Additonally, higher psychosis and obsessive subscale 
scores correlated with lower functional scores and higher mood subscale scores 
correlated with better motor performance (Kieburtz, 1996).  There was a high degree of 
reliability among the different UHDRS raters performing the motor assessment.  The 
scores on the motor, cognitive, and functional components were highly inter-correlated, 
with the exception of the behavioral assessment which did not correlate well (Kieburtz, 
1996).  Kieburtz et al. concluded that behavioral abnormalities, unlike the slow and 
  
 
steady deterioration of other domains, are heterogenous, episodic, and without clear 
progression.  Also noted was behavioral dysfunction is one of the symptoms of HD most 
amenable to symptomatic intervention and is therefore, less likely to be consistently 
observed over time (Kieburtz, 1996). 
Table 5 
Frequencies and Percentages for Frequency and Severity of Suicidal Ideation from the 
UHDRS 
Response n % 
    
Frequency of suicidal ideation   
 Not thinking about suicide or self-harm 5 3 
 Seldom thinking about suicide – less than once a month 88 54 
 Sometimes think about suicide – at least once a month 31 19 
 Frequently thinking about suicide – at least once a week 26 16 
 Often thinks about suicide – sometimes for days and week on 
end 
13 8 
Severity of suicidal ideation   
 No suicidal thoughts 40 25 
 No thoughts at current time, but person talks about suicide as 
option 
88 54 
 Seriously considered suicide but has no plan 25 15 
 Has a plan, but no active preparations 8 5 
 Has a plan and is actively preparing 2 1 
 
Ancillary Analysis 
 It is possible that CAG repeat length has an effect on depression, and that this 
effect is carried over into suicidal ideation.  An ordinal logistic regression was thus 
conducted to assess if depression mediates the relationship between CAG repeat length 
and suicidal ideation.  A Baron and Kenny mediation analysis was conducted to assess 
this potential relationship. To assess for mediation, three regressions were conducted.  
For mediation to be supported, four items must be met: 1) the independent variable must 
  
 
be related to the dependent variable, 2) the independent variable must be related to the 
mediator variable, 3) the mediator must be related to the dependent variable while in the 
presence of the independent variable, and 4) the independent variable should no longer be 
a significant predictor of the dependent variable in the presence of the mediator variable 
(Baron & Kenny, 1986).   
 The relationship between CAG repeat length and severity of suicidal ideation was 
not significant, and was not assessed any further.  However, the relationship between 
CAG repeat length and the frequency of suicidal ideation was significant, and the 
mediating effect of depression was assessed further in regards to this relationship.  Next, 
CAG repeat length was assessed for a relationship with depression (step 2) and did not 
relate to depression (p = .213). Thus, item 2 was not met, and the mediation analysis 
indicated no evidence of a mediating effect of depression on the relationship between 
CAG repeat length and suicidal ideation. 
Summary 
 Data analysis of 163 COHORT study subjects was completed. The findings 
indicate CAG repeat length does significantly predict the frequency of suicidal ideation, 
when controlling for depression, substance abuse history, and use of benzodiazepines.  
The results of the ordinal logistic regression showed significance, χ2(4) = 14.17, p = .007, 
suggesting that CAG length can predict the frequency of suicidal ideation.  Since the 
model was significant, the individual predictors were examined. Despite taking 
depression, benzodiazepine use, and history of substance abuse into account, there is still 
a predictive relationship between CAG repeat length and frequency of suicidal ideation.  
CAG repeat length was a significant predictor of frequency of suicidal ideation, p = .010, 
  
 
suggesting that as CAG repeat length increased, the likelihood of being in a higher 
category of frequency of suicidal ideation also tended to increase.  In summary, for every 
CAG length increase, there is a 0.09 increase in suicidal frequency. 
The results of the ordinal logistic regression did show significance, χ2(4) = 11.83, 
p = .019, suggesting that CAG repeat length predicted severity of suicidal ideation as 
well.  Since the model was significant, the individual predictors were examined.  The 
covariate depression was a significant predictor of severity of suicidal ideation, p = .003, 
suggesting that as depression increased, the likelihood of being in a higher category of 
severity of suicidal ideation also tended to increase.  Thus, when the effect of depression 
was taken into account, there was no significant relationship between CAG repeat length 
and the severity of suicidal ideation. 
Lastly, descriptive statistics were used to determine if the UHDRS behavioral 
assessment accurately represents the general Huntington’s disease population.  In this 
analysis, only 3% of patients did not think about suicide or self-harm at any time. The 
most commonly cited frequency of suicidal ideation was Seldom thinking about suicide – 
less than once a month, with 88 (54%) patients reported as falling into this category.  The 
least commonly cited frequency of suicidal ideation was Not thinking about suicide or 
self-harm, with 5 (3%) patients who were reported as falling into this category.  The 
average frequency rating for the entire sample was 1.72 (SD = 1.03).  The most 
commonly cited severity of suicidal ideation was No thoughts at current time, but person 
talks about suicide as a potential option, with 88 (54%) of patients reported as falling 
into this category.  The least commonly cited severity of suicidal ideation was Has a plan 
  
 
and is actively preparing, with 2 (1%) of patients reported as falling into this category.  
The average severity rating for the sample was 1.04 (SD = 0.84).    
This analysis does not fully answer whether the Unified Huntington’s Disease 
Rating Scale (UHDRS) behavioral assessment accurately represents suicidal behavior of 
Huntington’s disease patients.  Current literature cites the incidence and prevalence of 
suicide and the frequency of suicidality in Huntington’s disease, but not specifically the 
severity of suicidal behavior.  A literature review was completed to provide a comparison 
of the prevalence of suicidal ideation and suicide attempts in other Huntington’s disease 
studies. Wetzel et al. (2011) examined the presence of psychiatric comorbidity and its 
involvement in suicidal ideation in Huntington’s disease.  Suicidal ideation was evaluated 
in 1,941 HD patients enrolled in the Huntington Study Group.  Findings included suicidal 
ideation of 26.5 % and self-reported history of suicide attempts of 9.5 %, which were 
consistent with current literature (Cummings, 1995; Kessler et al., 2005). The rates of 
suicidal ideation and history of attempted suicide in HD are significantly elevated 
compared with rates in the general population. Kessler and colleagues (2005) reported 
that 3.3 percent of individuals in the 2001–2003 National Comorbidity Survey 
Replication report current suicidal ideation, and less than 1 percent of participants 
reported a history of a suicide attempt. Paulsen et al (2005) conducted a survey of 4171 
carriers of the Huntington’s gene with pre-manifest and manifest disease found that 
17.5% had suicidal thoughts at or around the time of assessment and 10% of those 
surveyed had made at least one suicide attempt in the past. Suicidal ideation was highest 
in gene carriers who were nearing the threshold of being diagnosed with manifest disease 
  
 
(those with early motor signs of Huntington’s disease), and in those who were beginning 
to lose their functional ability and independence (those with stage 2 disease).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Chapter 5 
Discussion 
Discussion 
 This chapter presents and summarizes the relationship between CAG length and 
suicidality in Huntington’s disease.  Huntington’s disease is a fully penetrant, autosomal 
dominant, inherited, progressive neurodegenerative disease that causes dysfunction of 
motor and emotional control, cognitive ability, and involuntary choreiform movements 
(Ha et al, 2012).    Huntington’s disease has been traditionally diagnosed in individuals 
having 36 or more cytosine, adenine, and guanine (CAG) repeats on the short arm of 
chromosome 4 (Rosenblatt et al., 1996).  As a result of this abnormality, a mutated 
huntingtin protein is produced.  The number of CAG repeats on the huntingtin gene may 
cause variations in clinical presentation.  HD research, involving genetics, has revealed 
variations in disease presentation, severity of symptoms, and age of onset related to the 
number of CAG repeats on the huntingtin gene (Rosenblatt et al., 1996).  In addition, 
there may be differences in clinical presentation, including severity of movement 
disorder, psychiatric disease, cognitive dysfunction, and metabolism depending on CAG 
repeat length (Rosenblatt et al., 1996). 
  Individuals with Huntington’s disease are more likely than the general population 
to commit suicide (Fiedorowicz, Mills, Ruggle, Langbehn, & Paulsen, 2011; Novak & 
Tabrizi, 2010).  A survey of 4171 carriers of the Huntington’s gene with pre-manifest and 
manifest disease found that 17.5% of suicidal thoughts occurred at or around the time of 
testing, and 10% of those had made at least one suicide attempt in the past (Novak & 
Tabrizi, 2010).  Suicidal ideation was highest in gene carriers who were beginning to 
  
 
become symptomatic and in those who were beginning to lose independence and 
functional ability (Novak & Tabrizi, 2010).  Risk factors for suicide are depression and 
impulsivity although some individuals with the disease have suicidal ideation in the 
absence of depression; for some, thoughts of suicide seem to be a rational response to 
their imminent loss of independence (Novak & Tabrizi, 2010).   
 In the general population, approximately 90% of individuals who complete 
suicide have a diagnosable psychiatric disorder at the time of death, substance abuse, or 
affective disorder (Bertolote et al, 2003; Cheng, 1995).  Other known risk factors for 
completed suicide include past suicide attempts, incarceration or arrest, access to suicidal 
means, family history of suicide, and current suicidal ideation (Druss & Pincus, 2000; 
Sher, 2006).  Brezo, Paris, & Turecki (2006) suggested that personality features, such as 
hopelessness, neuroticism, perfectionism, aggression, and irritability are associated with 
suicidality.  
 Suicide is one of the few potentially preventable causes of premature death in 
Huntington’s disease (Wetzel et al, 2011).  Completed suicide in HD has been reported to 
be as high as 13% (Cummings, 1995), a seven to twelve fold increase above that of the 
general population’s suicide rate of <1% (Farrer, 1986, Kessler et al, 2005).  Among 
neurodegenerative disease, suicide rates in Huntington’s disease remain the highest 
(Druss and Pincus, 2000). Farrer et al (1986) reported completed suicide rates in HD 
were 5.7% while 27.6% of individuals with HD admitted to at least one suicide attempt.  
The majority of research regarding suicide risk in HD has explored the relationship to 
genetic testing with less emphasis on suicidal ideation and risk over the course of the 
disease (Almqvist et al, 2003; Farrer, 1986). In order to assess which HD patients are at 
  
 
increased risk to commit suicide, it is first important to identify the specific population 
that may be at highest risk to target counseling and additional precautions (Paulsen et al, 
2005).Therefore, exploration and greater understanding of risk factors for suicide, such as 
CAG length, was worthy of further exploration.  
 The purpose of this quantitative analysis was to identify if there is a correlation 
between suicidality and CAG length in Huntington’s disease. The goal was to enable 
early identification, assessment, and treatment of suicidal behaviors to reduce the number 
of suicide attempts and suicide completions in the HD patient population. Some factors 
which may contribute to suicide risk have been identified, such as depression, history of 
substance abuse, and use of benzodiazepines, however no previous studies investigated 
the relationship between CAG repeat length and suicide in Huntington’s disease. This 
lead to the following research hypotheses: 
Hypothesis 1.  CAG repeat length significantly predicts the frequency of suicidal 
ideation, when controlling for depression, substance abuse history, and use of 
benzodiazepines 
An ordinal logistic regression was conducted to assess if CAG repeat length 
predicted frequency of suicidal ideation.  The results of the ordinal logistic regression 
showed significance, χ2(4) = 14.17, p = .007, suggesting that CAG predicted frequency of 
suicidal ideation.  Since the model was significant, the individual predictors were 
examined.  CAG repeat length was a significant predictor of frequency of suicidal 
ideation, p = .010, suggesting that as CAG repeat length increased, the likelihood of 
being in a higher category of frequency of suicidal ideation also tended to increase.  
Depression was also found to be a significant predictor of frequency of suicidal ideation, 
  
 
p = .004, suggesting that participants with depression had a higher likelihood of being in 
a higher category of frequency of suicidal ideation.  The relationship between CAG 
repeat length and the frequency of suicidal ideation was significant, and the mediating 
effect of depression was assessed further in regards to this relationship.  CAG repeat 
length was assessed for a relationship with depression and did not relate to depression (p 
= .213). 
Hypothesis 2.  CAG repeat length significantly predicts the severity of suicidal ideation, 
when controlling for depression, substance abuse history, and use of benzodiazepines. 
An ordinal logistic regression was conducted to assess if CAG repeat length 
predicted severity of suicidal ideation.  The results of the ordinal logistic regression 
showed significance, χ2(4) = 11.83, p = .019, suggesting that CAG repeat length 
predicted severity of suicidal ideation.  Since the model was significant, the individual 
predictors were examined.  The covariate depression was a significant predictor of 
severity of suicidal ideation, p = .003, suggesting that as depression increased, the 
likelihood of being in a higher category of severity of suicidal ideation also tended to 
increase.  Thus, when the effect of depression was taken into account, there was no 
significant relationship between CAG repeat length and the severity of suicidal ideation. 
Hypothesis 3.  The UHDRS behavioral assessment accurately represents suicidal 
behavior of Huntington’s disease patients. 
This analysis does not fully answer whether the Unified Huntington’s Disease 
Rating Scale (UHDRS) behavioral assessment accurately represents suicidal behavior of 
Huntington’s disease patients.  Current literature cites the incidence and prevalence of 
suicide and the frequency of suicidality in Huntington’s disease, but not specifically the 
  
 
severity of suicidal behavior.  Further research is needed to determine if the UHDRS 
behavioral assessment is a true representation of suicidality in HD. 
Implications 
Assessing or treating a suicidal patient represents one of the most challenging 
tasks a clinician has to face in their professional life, both intellectually and emotionally. 
Currently, there is little guidance to help clinicians identify and treat an individual with 
HD who is contemplating a fatal act.  CAG repeat length may be an important tool for 
clinicians to identify individuals with HD who have a greater risk for suicidal tendencies. 
The objective is to identify potential risk factors for suicidal behavior so that high risk 
patients may be prioritized. Research has shown that between 40-60% of individuals who 
commit suicide had seen a physician in the month prior to suicide; of these most had seen 
a general physician rather than a psychiatrist (Bertolote, 2000).  The implications of this 
research for patient management is the recognition that CAG repeat length can be a 
predictor of suicide frequency. The ultimate goal is to provide clinicians with adequate 
education and resources to identify these high risk individuals so patients may receive 
appropriate and timely intervention.  
Currently, there are no clinical guidelines for the management of a suicidal 
Huntington’s disease patient.  In 2014, the World Health Organization (WHO) published 
“Preventing Suicide: A Resource for General Physicians”, which is a series of resources 
addressed to specific social and professional groups particularly relevant to the 
prevention of suicide in general. Although not specific to HD, the World Health 
Organization provided a list of high risk socio-demographic factors to help guide 
clinicians in the identification of suicidal patients: 
  
 
HOW TO IDENTIFY PATIENTS AT HIGH RISK OF SUICIDAL BEHAVIOUR 
A number of clinically useful individual and socio-demographic factors are 
associated with suicide. They include: 
• Psychiatric disorders (generally depression, alcoholism and personality disorders); 
• Physical illness (terminal, painful or debilitating illness, AIDS); 
• Previous suicide attempts; 
• Family history of suicide, alcoholism and/or other psychiatric disorders; 
• Divorced, widowed or single status; 
• Living alone (socially isolated); 
• Unemployed or retired; 
• Bereavement in childhood.  
If the patient is under psychiatric treatment, the risk is higher in: 
• Those who have recently been discharged from hospital; 
• Those who have made previous suicide attempts. (WHO, 2014) 
In addition, recent life stressors associated with increased risk of suicide include: (WHO, 
2014) 
• Marital separation; 
• Bereavement: 
• Family disturbances; 
• Change in occupational or financial status; 
• Rejection by a significant person; 
• Shame and threat of being found guilty. 
  
 
The following recommendations for the management of suicidal patients in 
general were made by the World Health Organization in 2014: (WHO, 2014) 
MANAGEMENT OF SUICIDAL PATIENTS 
If a patient is emotionally disturbed, with vague suicidal thoughts, the opportunity 
of ventilating thoughts and feelings to a physician who shows concern may be sufficient 
(WHO, 2014).  Whatever the problem, the feelings of the suicidal person are usually a 
triad of helplessness, hopelessness and despair (WHO, 2014).  The three most common 
states are: 
1. Ambivalence. The majority of suicidal patients are ambivalent till the very end. There 
is a see-saw battle between the wish to live and the wish to die. If the ambivalence is used 
by the physician to increase the wish to live, the suicide risk may be reduced (WHO, 
2014). 
2. Impulsivity. Suicide is an impulsive phenomenon and impulse by its very nature is 
transient. If support is provided at the moment of impulse, the crisis may be defused 
(WHO, 2014).  
3. Rigidity. Suicidal people are constricted in their thinking, mood and action and their 
reasoning is dichotomized in terms of either/or. By exploring several possible alternatives 
to death with the suicidal patient, the physician gently makes the patient realize that there 
are other options, even if they are not ideal (WHO, 2014). 
Enlisting support 
The physician should assess the available support systems, identify a relative, 
friend, acquaintance or other person who would be supportive to the patient, and solicit 
that person’s help (WHO, 2014). 
  
 
Contracting 
Entering into a “no suicide” contract is a useful technique in suicide prevention. 
Other people close to the patient can be included in negotiating the contract. The 
negotiation of the contract can promote discussion of various relevant issues. In the 
majority of instances patients respect the promises they give to a physician. Contracting 
is appropriate only when patients have control over their actions (WHO, 2014). 
In the absence of severe psychiatric disorder or suicidal intent, the physician can initiate 
and arrange pharmacological treatment, generally with antidepressants, and psychological 
(cognitive behaviour) therapy (WHO, 2014). The majority of people benefit from 
continuing contacts; these should be structured to meet individual needs (WHO, 2014). 
 The recommendations for suicide prevention from the World Health Organization 
are a valuable resource for general physicians, however there are no current guidelines 
for clinicians who specifically treat Huntington’s disease patients.  The Huntington’s 
disease Society of America (HDSA) is a national, voluntary health organization dedicated 
to improving the lives of people with Huntington's disease and their families.  The 
mission statement of the HDSA emphasizes a desire to promote and support research and 
medical efforts to eradicate Huntington's disease, to assist people and families affected by 
Huntington's disease to cope with the problems presented by the disease, and to educate 
the public and health professionals about Huntington's disease (HDSA, 2014).  In 2011, 
the Huntington’s disease Society of America released, “A Physician’s Guide to the 
Management of Huntington’s Disease, Third Edition”.  Chapter 6, “The Psychiatric 
Disorder”, was authored by Adam Rosenblatt, M.D.  Dr. Rosenblatt wrote in his preface, 
“Psychiatric symptoms have long been understood to be a common and inherent part of 
  
 
Huntington’s disease (HD). In the classic description of the condition which bears his 
name, George Huntington referred to “the tendency to insanity, and sometimes that form 
of insanity which leads to suicide…” (Nance, Paulsen, Rosenblatt, & Wheelock, 2011) 
Most physicians understand this in the abstract, yet people with HD with psychiatric 
problems suffer from under-diagnosis and under-treatment (Nance et al., 2011). This is 
regrettable, because psychiatric problems in HD are often the most disabling and yet the 
most treatable” (Nance et al., 2011).   Chapter 6 included diagnostic and treatment 
recommendations for depression, obsessive and compulsive behavior, and delusions and 
hallucinations in the Huntington’s disease patient. Also included was a small section on 
suicide in the Huntington’s disease patient, which reads as follows (Nance et al., 2011):  
“Suicide is alarmingly common in people with HD, possibly because of the 
frequent co-morbidity of depression and personality changes resulting in disinhibition 
and impulsive behavior, but that does not mean that suicide is not preventable. Depressed 
individuals should always be asked about suicide, and this should be regularly re-
assessed. It is a misconception that suicidal individuals will not admit to these feelings. 
The question should be asked in a non-intimidating, matter-of-fact way, such as “Have 
you been feeling so bad that you sometimes think life isn’t worth living?” Or, “Have you 
even thought about suicide?” If the person acknowledges these feelings, the clinician 
needs to ask more questions to evaluate the severity of the situation and decide on the 
best course of action. Are the feelings just a passive wish to die or has the person actually 
thought out a specific suicidal plan? Does the person have the means to commit suicide? 
Has she prepared for a suicide, such as by loading a gun or hoarding pills? Can the person 
identify any factors which are preventing her from killing herself? What social supports 
  
 
are present? Some individuals, although having suicidal thoughts, may be at low risk if 
they have a good relationship with their doctor, have family support, and have no specific 
plans. Others may be so dangerous to themselves that they require emergency 
hospitalization.  Although there are instances of non-depressed individuals with HD 
harboring chronic suicidal feelings, most, if not all, suicidal people with HD are suffering 
from major depression and can be treated successfully. In cases of completed suicide in 
HD of which there are first-hand knowledge, the person was usually well understood by 
his family to be suffering from depression and attempts at treatment had been initiated, 
but sadly proved insufficient. If the clinician is unsure, the person should be treated 
presumptively. This is not to say that a person with HD, particularly early in the course of 
the disease, may not express a fear of becoming helpless one day, or a desire not to live 
past a certain degree of impairment. A physician should listen supportively to these 
concerns, realizing that most individuals in this situation will be able to adapt if they are 
not suffering from depression” (Nance et al., 2011).   
One of the clinical implications of this research would be the use of CAG repeat 
length in risk factor assessment for suicidality in the HD population. CAG repeat length 
may be used as a method to screen for individuals with a higher suicide risk so that 
preventative measures may be taken prophylactically. Individuals with high CAG repeat 
lengths can be assessed earlier and in more depth for suicidal behavior. As a result of 
early intervention, individuals can contract for safety and be offered psychotherapy, 
psychiatric consultation, support groups, and anti-depressant medication if indicated. 
Home evaluations can be conducted to evaluate if there are weapons or means of suicide 
  
 
assessable to the patient. The development of suicide guidelines for Huntington’s disease 
patients would be a valuable resource for clinicians in the future.   
Recommendations 
One of the important messages from Dr. Rosenblatt’s recommendations was 
suicide is “preventable”. Proper identification of the risk factors for suicide in 
Huntington’s disease followed by aggressive intervention may allow suicide to be a 
“preventable” complication of HD.  The findings from this quantitative analysis support 
using CAG length in a clinician’s risk factor assessment to determine the frequency of 
suicidality.  A future recommendation includes the development of suicide prevention 
guidelines for clinicians who care for Huntington’s disease patients. Guidelines may 
include the use of CAG repeat length in the risk stratification analysis for suicidality in 
HD. 
This analysis does not fully answer research question number three, “does the 
Unified Huntington’s Disease Rating Scale (UHDRS) behavioral assessment accurately 
represent the suicidal behavior of Huntington’s Disease patients?”  Current literature cites 
the incidence and prevalence of suicide and the frequency of suicidality in Huntington’s 
disease, but not specifically the severity of suicidal behavior.  Future recommendations 
would also include further analysis particularly directed at evaluating the severity of 
suicidal behavior in the Huntington’s disease population. 
Lastly, the scores on the motor, cognitive, and functional components of the 
Unified Huntington’s Disease Rating Scale were validated and highly inter-correlated 
among raters, with the exception of the behavioral section (Kieburtz, 1995).  In the 
behavioral section, the rater must formulate a clinical impression of mood based upon 
  
 
individual responses to questions. The total behavioral score did not correlate with any of 
the other assessments in the analysis by Kieburtz et al. in 1995, however, higher mood 
sub-scale scores correlated with better motor performance and higher psychosis and 
obsessive sub-scale scores correlated with lower functional scores (Kieburtz, 1995).  
These findings reflect that behavioral abnormalities, unlike the slow progression in other 
domains, are heterogeneous and episodic (Kieburtz, 1995).  Also noted is the fact that 
behavioral disturbances in Huntington’s disease are more likely to improve with 
symptomatic intervention compared to motor symptoms (Kieburtz, 1995).  A final 
recommendation would be to future research to analyze the behavioral component of the 
UHDRS to determine if direct patient questioning would be more reliable than rater 
summation of responses. 
Beyond this analysis, the COHORT database is a valuable resource to HD 
investigators and may lead to other research opportunities.  The phenotypic and 
genotypic data can be assessed by potential investigators by submitting a brief research 
proposal to cohort.projectmanager@ctcc.rochester.edu (HSG, 2014). 
Limitations and Delimitations 
 While the Huntington Study Group COHORT database used in this investigation 
has tremendous value and potential, it does have several limitations.  This research 
population involves participants who are predominantly Caucasian and relatively highly 
educated, which may not be representative of the general HD population.  Additionally, 
individuals in the COHORT study were primarily from only three countries which may 
limit certain ethnicities from participation.  Study participants were enrolled at clinical 
research sites that are members of the Huntington Study Group (HSG).  HSG research 
  
 
sites, for the most part, are large academic institutions with dedicated movement disorder 
centers. This too may not be representative of the general Huntington’s disease 
population as many individuals with HD do not live within close proximity to these type 
of specialized centers. The cohorts used in these analyses are out-patient, ambulatory 
participants, thus limiting conclusions with respect to individuals with advanced disease 
and/or higher severity of motor signs. Many patients with end-stage HD reside in nursing 
facilities which would limit access to research opportunities.  Lastly, individuals who 
participate in clinical trials tend to be more compliant with keeping appointments and 
adhering to treatment plans. In addition, there is typically greater familial support and 
willingness to assist with transportation to research visits. As a result of these limitations, 
the data used from participants in the COHORT Study database may not be 
representative of the general HD population. 
 The Unified Huntington's Disease Rating Scale (UHDRS) is the current ‘gold-
standard’ outcome measure used in HD research. The UHDRS is divided into multiple 
subscales, assessing motor and cognitive function, behavioral (i.e., psychiatric) 
symptoms, and functional capacity. The scale was developed and tested in gene 
expansion carriers who had manifest motor symptoms of HD, may not be sensitive to 
changes in the earlier stages of the disease.  The UHDRS Behavioral Subscale includes 
11 items that independently assess frequency and severity of psychiatric-related 
symptoms. The UHDRS Motor and Behavioral Subscales were administered to each 
patient at each visit by a qualified rater.  A qualified rater for the COHORT Study is an 
experienced investigator that has been deemed competent to administer the UHDRS by 
the Huntington Study Group. In the behavioral section of the UHDRS, the investigator 
  
 
asks the participant questions about sad/mood, low self-esteem/guilt, anxiety, suicidal 
thoughts, disruptive/aggressive behavior, irritable behavior, obsessions, compulsions, 
delusions, and hallucinations. The rater must then rate both the frequency and severity of 
the behavior on a scale from 0 (absent) to 4 (severe).   In the behavioral section, the rater 
must formulate a clinical impression of mood based upon individual responses to 
questions.  Rater errors can occur when an investigator observes and evaluates a 
participant.  Personal perceptions and biases may influence how an individual’s 
performance is scored. In addition, individuals with HD may not respond in the same way 
to investigator questioning than if the questions were given in the form of a questionnaire 
which could be completed privately.  Lastly, due to the likelihood of cognitive 
dysfunction associated with HD, individuals may not have the self-awareness to 
acknowledge or express the degree of behavioral symptoms that are actually present. 
Summary 
Overview 
Huntington’s disease (HD) is an autosomal dominant, progressive 
neurodegenerative disorder, causing atrophy of the basal ganglia, specifically the caudate 
nucleus, putamen, and globus nucleus (Novak & Tabrizi, 2010; Roos, 2010; Ross & 
Tabrizi, 2011).  The disease is characterized by choreiform movements, dystonia, mood 
and personality disorders, and cognitive impairment (Novak & Tabrizi, 2010; Ross & 
Tabrizi, 2011).  Approximately 30,000 people in the United States (US) have clinical 
manifestations of HD, and an additional 150,000 healthy people are thought to be 
immediately at risk of developing HD (HSG, 2011). Huntington’s disease has been 
traditionally diagnosed in individuals having 36 or more cytosine, adenine, and guanine 
  
 
(CAG) repeats on the short arm of chromosome 4 (Rosenblatt et al., 1996).  As a result of 
this abnormality, a mutated huntingtin protein is produced.  The number of CAG repeats 
on the huntingtin gene may cause variations in clinical presentation.  In addition, there 
may be differences in clinical presentation, including severity of movement disorder, 
psychiatric disease, cognitive dysfunction, and metabolism (Rosenblatt et al., 1996).   
Individuals with Huntington’s disease are more likely than the general population to 
commit suicide (Fiedorowicz, Mills, Ruggle, Langbehn, & Paulsen, 2011; Novak & 
Tabrizi, 2010).   
Research Hypotheses  
The purpose of this study was to determine if a correlation exists between suicide 
and CAG repeat length.  Specifically, if CAG length is a diathesis or pre-disposition for 
suicidal behavior in Huntington’s disease.  Some factors, which may contribute to suicide 
risk, have previously been identified, but no studies have investigated if there is a 
correlation between CAG length and suicide in Huntington’s disease, which leads to the 
following hypotheses.  
Hypothesis 1.  CAG repeat length significantly predicts the frequency of suicidal 
ideation, when controlling for depression, substance abuse history, and use of 
benzodiazepines 
Hypothesis 2.  CAG repeat length significantly predicts the severity of suicidal 
ideation, when controlling for depression, substance abuse history, and use of 
benzodiazepines. 
Hypothesis 3.  The UHDRS behavioral assessment accurately represents suicidal 
behavior of Huntington’s disease patients. 
  
 
Methodology 
Research Methods and Procedures 
The Cooperative Huntington Observational Research Trial is an observational 
study designed to collect phenotypic data and biological samples from individuals with 
HD and their family members.  A case-control study, using the COHORT Study de-
identified database, will be conducted to determine if there is a correlation between 
suicide and CAG length.  The COHORT database includes clinical assessments and 
genetic testing from 2,318 individuals collected by the Huntington Study Group over a 5-
year period of time from 2005 to 2010 (HSG, 2011).  The institutional review board of 
the University of Rochester and each site approved the protocol.  To protect the 
confidentiality and data of participants, all were assigned a unique identification number 
without identifying information (HSG, 2011).  The COHORT study involved (a) a 
baseline visit, comprising an assessment with the Mini-Mental State Examination; (b) a 
neurological and physical examination, including body mass index; and (c) the Unified 
Huntington's Disease Rating Scale 99 (UHDRS 99), conducted by trained study 
personnel.  The UHDRS 99 evaluated four domains, consisting of motor function, 
cognition, behavior, and functional capacity.  To determine if there is a correlation 
between CAG length and suicide, focus would be placed on the suicidal thought 
assessment, which evaluated suicidal thoughts, suicidal intention, and preparation for the 
act of suicide.  In a secondary analysis of COHORT, data pertaining to the Unified 
Huntington’s Disease Rating Scale behavioral assessment and death records will be 
evaluated to determine if there is a predictive relationship between CAG repeat length 
  
 
and suicidality.  A correlation analysis will be made to determine of a predictive 
relationship exists between these two variables.   
Sample 
Of the 2,318 individuals, one completed suicide in an individual with clinically 
diagnosed HD and 11 suicide attempts (nine in individuals with clinically diagnosed HD) 
occurred.  The individual who committed suicide had reported a prior history of 
depression and multiple previous suicide attempts.  For the 11 participants who attempted 
suicide, nine (82%) were female, the mean age was 43.4 (range 26–55), seven (64%) had 
reported a prior history of depression, and four (36%) had reported a history of at least 
one previous suicide attempt.  Suicides and suicide attempts were prospectively assessed 
and reported within three working days after a research site became aware of the event.   
Data Analysis 
Research Question One 
Does CAG repeat length significantly predict the frequency of suicidal ideation, when 
controlling for depression, substance abuse history, and use of benzodiazepines? 
To address research question one, ordinal logistic regression was conducted.  CAG repeat 
length was the independent, or predictor variable.  Depression, substance abuse history 
and use of benzodiazepines was covariates, and responses to the UHDRS survey items 
pertaining to the frequency of suicidal ideation (“feels life is not worth living”, “has 
suicidal thoughts”) formed the dependent variable.  CAG length represented the amount 
of CAG repeats on the short arm of chromosome 4, and suicidal ideation frequency was 
representative of responses to the UHDRS survey items pertaining to the frequency of a 
patient’s suicidal ideation.  The χ2 test was used to assess whether the set of independent 
  
 
variables collectively predicts the dependent variable.  The pseudo R2, was reported and 
used to determine how well variations in the dependent variable can be accounted for by 
the set of independent variables.  The Wald statistic was used to determine the 
significance of each predictor. 
Research Question Two 
Does CAG repeat length significantly predict the severity of suicidal ideation, when 
controlling for depression, substance abuse history, and use of benzodiazepines? 
To address research question two, ordinal logistic regression was conducted.  In the 
proposed analysis, CAG repeat length of Huntington’s disease sufferers was the 
independent, or predictor variable.  Depression, substance abuse history and use of 
benzodiazepines were the covariates, and responses to the UHDRS survey items 
pertaining to the severity of suicidal ideation (“feels life is not worth living”, “has 
suicidal thoughts”) were the dependent variable.  CAG length represented the amount of 
CAG repeats on the short arm of chromosome 4, and suicidal ideation severity will be 
representative of the responses to the UHDRS survey items pertaining to the severity of a 
patient’s suicidal ideation.  The standard method entered all independent variables 
(predictors) simultaneously into the model.  The χ2 test was used to assess whether the 
set of independent variables collectively predicts the dependent variable.  The pseudo R2, 
was reported and used to determine how well variations in the dependent variable can be 
accounted for by the set of independent variables.  The Wald statistic was used to 
determine the significance of each predictor. 
Research Question Three 
  
 
Does the UHDRS behavioral assessment accurately represent suicidal behavior of 
Huntington’s disease patients? 
To address research question three, descriptive statistics were conducted on responses to 
the UHDRS for the sample.  Means and standard deviations were calculated for the 
suicidal behavior subscales of the UHDRS assessment to provide average responses, 
while frequencies and percentages will indicate how many participants were ranked as 
“absent,” “slight / questionable,” “mild,” “moderate,” or “severe” for the severity and 
frequency of each suicidal behavior.   
Results 
Responses were collected from 163 participants.  142 participants (87%) recorded a 
response of 0 for drug abuse, two participants (1%) recorded a response of 1 for drug 
abuse, and 19 participants (12%) recorded a response of 2 for drug abuse.  Forty-eight 
participants (29%) recorded a response of 0 for depression and 115 participants (71%) 
recorded a response of 1 for depression.  One hundred and eighteen participants (72%) 
responded “No” to Benzodiazepine use and 45 participants (28%) responded “Yes” to 
Benzodiazepine use.  Results for the occurrence of each confounding variable can be 
found in Table 1. 
Table 1 
Frequencies for each Control Variable in the Sample 
Response N % 
    
Drug use   
 No 142 87 
 Yes, active 2 1 
 Yes, not active 19 12 
History of depression   
 No depression 48 29 
  
 
 Depression 115 71 
Benzodiazepine use   
 No 118 72 
 Yes 45 28 
 
 The mean amount for CAG repeat length in the sample was 43.69 (SD = 4.09).  
Results for the descriptive statistics for CAG repeat length can be found in Table 2.  
Table 2 
Descriptive Statistics for CAG Repeat Length 
Variable Minimum Maximum Mean Std. Deviation 
     
CAG Repeat 
Length 
38 59 43.69 4.09 
 
An ordinal logistic regression was conducted to assess if CAG repeat length 
predicted frequency of suicidal ideation.  Prior to analysis, the assumption of proportional 
odds was assessed by using the test of parallel lines.  Results of the test of parallel lines 
were not significant (p = .993) and the assumption was met.  The results of the ordinal 
logistic regression showed significance, χ2(4) = 14.17, p = .007, suggesting that CAG 
predicted frequency of suicidal ideation.  Since the model was significant, the individual 
predictors were examined.  CAG repeat length was a significant predictor of frequency of 
suicidal ideation, p = .010, suggesting that as CAG repeat length increased, the likelihood 
of being in a higher category of frequency of suicidal ideation also tended to increase.  
Depression was also found to be a significant predictor of frequency of suicidal ideation, 
p = .004, suggesting that participants with depression had a higher likelihood of being in 
a higher category of frequency of suicidal ideation.  Results of the ordinal logistic 
regression are presented in Table 3.  
  
 
Table 3 
Ordinal Logistic Regression for CAG Repeat Lengths, Drug Abuse, Depression, and 
Benzodiazepine Use Predicting Frequency of Suicidal Ideation 
 
Variable 
 
B 
 
SE 
 
Z 
 
p 
95% Confidence Interval 
Lower 
Bound 
Upper 
Bound 
       
Drug Abuse -.30 0.23 -1.28 .200 0.47 1.17 
Depression 1.03 0.36 2.88 .004 1.39 5.69 
Benzodiazepine Use -
0.03 
0.34 -0.08 .934 0.50 1.89 
CAG Repeat Length 0.09 0.04 2.59 .010 1.02 1.18 
 
 An ordinal logistic regression was conducted to assess if CAG repeat length 
predicted severity of suicidal ideation.  Prior to analysis, the assumption of proportional 
odds was assessed by using the test of parallel lines.  Results of the test of parallel lines 
were not significant (p = .107) and the assumption was met. The results of the ordinal 
logistic regression showed significance, χ2(4) = 11.83, p = .019, suggesting that CAG 
repeat length predicted severity of suicidal ideation.  Since the model was significant, the 
individual predictors were examined.  The covariate depression was a significant 
predictor of severity of suicidal ideation, p = .003, suggesting that as depression 
increased, the likelihood of being in a higher category of severity of suicidal ideation also 
tended to increase.  Thus, when the effect of depression was taken into account, there was 
no significant relationship between CAG repeat length and the severity of suicidal 
ideation.  Results of the ordinal logistic regression are presented in Table 4.   
Table 4 
Ordinal Logistic Regression for CAG Repeat Lengths, Drug Abuse, Depression, and 
Benzodiazepine Use Predicting Severity of Suicidal Ideation 
 
Variable 
 
B 
 
SE 
 
Z 
 
p 
95% Confidence Interval 
Lower 
Bound 
Upper 
Bound 
  
 
       
Drug Abuse -0.27 0.24 -1.16 .247 0.48 1.21 
Depression 1.02 0.35 2.95 .003 1.41 5.46 
Benzodiazepine Use -0.38 0.34 -1.11 .267 0.35 1.34 
CAG Repeat Length 0.06 0.04 1.73 .084 0.99 1.15 
       
 
Suicidal ideation was measured on the psychiatric portion of the UHDRS and was 
scored in terms of frequency and severity. Frequency scores were: 0= almost never, 1= 
seldom, 3= sometimes, 4= almost always. Severity scores were measured similarly: 0= 
almost never, 1= slight, 2= mild, 3= moderate, 4= severe.  Frequencies and percentages 
were calculated along with the proposed means and standard deviations to allow a 
comprehensive view of these responses.  The most commonly cited frequency of suicidal 
ideation was Seldom thinking about suicide – less than once a month, with 88 (54%) 
patients reported as falling into this category.  The least commonly cited frequency of 
suicidal ideation was Not thinking about suicide or self-harm, with 5 (3%) patients who 
were reported as falling into this category.  The average frequency rating for the entire 
sample was 1.72 (SD = 1.03). 
 The most commonly cited severity of suicidal ideation was No thoughts at current 
time, but person talks about suicide as a potential option, with 88 (54%) of patients 
reported as falling into this category.  The least commonly cited severity of suicidal 
ideation was Has a plan and is actively preparing, with 2 (1%) of patients reported as 
falling into this category.  The average severity rating for the sample was 1.04 (SD = 
0.84).  Descriptive statistics for the frequencies of each response are presented in Table 5. 
 This analysis does not fully answer whether the Unified Huntington’s Disease 
Rating Scale (UHDRS) behavioral assessment accurately represents suicidal behavior of 
  
 
Huntington’s disease patients.  Current literature cites the incidence and prevalence of 
suicide and the frequency of suicidality in Huntington’s disease, but not specifically the 
severity of suicidal behavior. Wetzel et al. (2011) evaluated the role of co-morbidity in 
suicidal ideation in Huntington’s disease.    
Table 5 
Frequencies and Percentages for Frequency and Severity of Suicidal Ideation from the 
UHDRS 
Response n % 
    
Frequency of suicidal ideation   
 Not thinking about suicide or self-harm 5 3 
 Seldom thinking about suicide – less than once a month 88 54 
 Sometimes think about suicide – at least once a month 31 19 
 Frequently thinking about suicide – at least once a week 26 16 
 Often thinks about suicide – sometimes for days and week on 
end 
13 8 
Severity of suicidal ideation   
 No suicidal thoughts 40 25 
 No thoughts at current time, but person talks about suicide as 
option 
88 54 
 Seriously considered suicide but has no plan 25 15 
 Has a plan, but no active preparations 8 5 
 Has a plan and is actively preparing 2 1 
 
Ancillary Analysis 
 It is possible that CAG repeat length has an effect on depression, and that this 
effect is carried over into suicidal ideation.  An ordinal logistic regression was thus 
conducted to assess if depression mediates the relationship between CAG repeat length 
and suicidal ideation.  A Baron and Kenny mediation analysis was conducted to assess 
this potential relationship. To assess for mediation, three regressions were conducted.  
For mediation to be supported, four items must be met: 1) the independent variable must 
  
 
be related to the dependent variable, 2) the independent variable must be related to the 
mediator variable, 3) the mediator must be related to the dependent variable while in the 
presence of the independent variable, and 4) the independent variable should no longer be 
a significant predictor of the dependent variable in the presence of the mediator variable 
(Baron & Kenny, 1986).  The relationship between CAG repeat length and severity of 
suicidal ideation was not significant, and was not assessed any further.  However, the 
relationship between CAG repeat length and the frequency of suicidal ideation was 
significant, and the mediating effect of depression was assessed further in regards to this 
relationship.  Next, CAG repeat length was assessed for a relationship with depression 
(step 2) and did not relate to depression (p = .213). Thus, item 2 was not met, and the 
mediation analysis indicated no evidence of a mediating effect of depression on the 
relationship between CAG repeat length and suicidal ideation. 
Limitations and Delimitations 
 While the Huntington Study Group COHORT database used in this investigation 
has tremendous value and potential, it does have several limitations.  This research 
population involves participants who are predominantly Caucasian and have relatively 
high educational levels. Study participants were enrolled at clinical research sites that are 
members of the Huntington Study Group (HSG).  HSG research sites, for the most part, 
are large academic institutions with dedicated movement disorder centers. This too may 
not be representative of the general Huntington’s disease population as many individuals 
with HD do not live within close proximity to these type of specialized centers.  As a 
result of these limitations, the data used from participants in the COHORT Study 
database may not be representative of the general HD population. 
  
 
 The Unified Huntington's Disease Rating Scale (UHDRS) is the current ‘gold-
standard’ outcome measure used in HD research. The UHDRS Motor and Behavioral 
Subscales were administered to each patient at each visit by a qualified rater.  A qualified 
rater for the COHORT Study is an experienced investigator that has been deemed 
competent to administer the UHDRS by the Huntington Study Group.  In the behavioral 
section, the rater must formulate a clinical impression of mood based upon individual 
responses to questions.  Rater errors can occur when an investigator observes and 
evaluates a participant.  Personal perceptions and biases may influence how an 
individual’s performance is scored.  Lastly, individuals with HD may not respond in the 
same way to investigator questioning than if the questions were given in the form of a 
questionnaire which could be completed privately.   
Recommendation 
The findings from this quantitative analysis support using CAG length in a 
clinician’s risk factor assessment to determine the frequency of suicidality.  A future 
recommendation includes the development of suicide prevention guidelines for clinicians 
who care for Huntington’s disease patients. Guidelines may include the use of CAG 
repeat length in the risk stratification analysis for suicidality in HD. 
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